Complete if Known Substitute for form 1449A-B/PTO **Application Number** 09/724,869 November 28, 2000 Filing Date INFORMATION DISCLOSURE First Named Inventor Juha Punnonen, et al. STATEMENT BY APPLICANT Group Art Unit 1639 **Examiner Name** Teresa D. Wessendorf (use as many sheets as necessary) Attorney Docket Number 0155.130US

		U.S. Patent Doo	ument	Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,	
Examiner Initials	Cite No.	Number	Kind Code (if known)		Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appeal	
tow	1	5,718,883		Harlan et al.	02-17-1998		
' [2	5,738,852		Robinson et al.	04-14-1998	RECEI	\ /r
•	3	5,858,776		Ostrand-Rosenberg et al.	01-12-1999	, LOLI	VL
	4	5,861,310		Freeman et al.	01-19-1999]
1	5	6,071,716		Freeman et al.	06-06-2000	MAY 0 2	200
7	6	6,084,067		Freeman et al.	07-04-2000	1 0 2	kuu
1	7	6,149,905		Ostrand-Rosenberg et al.	11-21-2000	YECH CENTER 1	

	FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.	Office	Foreign Patent Docum Number	ent Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
taw	8	wo	94/24267		Robinson, William S.	10-27-1994		
TOW	9	wo	95/23859		Brigham & Women's Hospital; Dana-Farber Cancer Institute	09-08-1995		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials No		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).	Т
Tau	Fargeas, C.A., et al., "Identification of Residues in the V Domain of CD80 (B7-1) Implicated in Func Interactions with CD28 and CTLA-4," Journal of Experimental Medicine 182(3):667-675 (1995)		
j	11	Freeman, G.J. et al., "Cloning of B7-2: A CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation," Science 262:909-911 (1993)	
į.	12	Guo, Y., et al., "Mutational Analysis and an Alternatively Spliced Product of B7 Defines Its CD28/CTLA-4 binding Site on Immunoglobulin C-like Domain," Journal of Experimental Medicine 181(4):1345-1355 (1995)	
9	13	He, X-S. et al., "Costimulatory protein B7-1 enhances the cytotoxic T cell response and antibody response to hepatitis B surface antigen," Proc. Natl. Acad. Sci. USA 93:7274-7278 (1996)	
-	14	Kim, J.J. et al., "Engineering DNA Vaccines via Co-delivery of Co-Stimulatory Molecule Genes," Vaccine 16(19):1828-1835 (1998)	
0	15	Kuchroo, V.K. et al.," B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2 Developmental Pathways: Application to Autoimmune Disease Therapy," Cell 80:707-718 (1995)	
ā	16	Metzler, W., et al., "Solution Structure of Human CTLA-4 and Delineation of a CD80/CD86 Binding Site Conserved in CD28," Nature Structural Biology 4(7):527-531 (July 1997)	
	17	Parsons, K.R., et al., "Cloning of Cattle CD80," Immunogenetics 49(3):231-234 (1999)	

Examiner Signature	7. Wessely	Date Considered	c/16	10	, Z	
				,		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

0155.130US

Complete if Known Substitute for form 1449A-B/PTO **Application Number** 09/724,869 November 28, 2000 Filing Date INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor Juha Punnonen, et al. **Group Art Unit** 1639 **Examiner Name** Teresa D. Wessendorf (use as many sheets as necessary)

Attorney Docket Number

the	18	Peach, R.J., et al., "Both Extracellular Immunoglobulin-like Domains of CD80 Contain Residues Critical for Binding T Cell Surface Receptors CTLA-4 and CD28," Journal of Biological Chemistry 270(36):21181-21187 (1995)
	19	Rennert, P. et al., "The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion," International Immunology 9(6):805-813 (1997)
Ψ	20	Wu, Y., "CTLA-4-B7 Interaction is Sufficient to Costimulate T Cell Clonal Expansion," J. Exp. Med. 185(7):1327-1335 (1997)

Examiner Signature	T. Wend	Date Considered	6/1	16/03

(Modified) PTO/SB/08A-B (10-96) Approved for use through 10/31/99. OMB 0651-0031

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

BK C	omplete if Known
Application Number	09/724,869
Filing Date	November 28, 2000
First Named Inventor	Juha Punnonen
Group Art Unit	1827- [639
Examiner Name	Unassigned T. Westersky
Attorney Docket Number	02-030310US
Date Submitted	May 21, 2002

	r	U.S. Patent Document		S. PATENT DOCUMENTS Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, lines,
Examiner Initials	Cite No.	Number Kir	nd Code known)	Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
The	1	5,252,714		Harris et al.	10-12-1993	
r.	2	5,264,563		Huse	11-23-1993	
	3	5,338,665		Schatz Et al	08-16-1994	
	4	5,348,867		Georgiou et al.	09-20-1994	051/5
1	5	5,470,725		Borriss et al.	11-28-1995	RECEIVE
	6	5,512,463		Georgiou et al.	09-20-1994	JUN 1. 0 2002
	7	5,514,588		Varadaraj	05-07-1996	
	8	5,523,388		Huse	06-04-1996	TECH CENTER 1600/2
\	9	5,571,698		Ladner et al.	11-05-1996	
,	10	5,589,466		Felgner et al.	12-31-1996	000000000000000000000000000000000000000
Ψ.	11	5,593,972		Weiner et al.	01-14-1997	COPY OF PAPERS ORIGINALLY FILE
Vatrie	12	5,605,793		Stemmer et al	02-25-1997	
tow	13	5,691,170		Gritz et al.	11-25-1997	
ŀ	14	5,698,426		Huse	12-16-1997	
`	15	5,703,057		Johnston et al.	12-30-1997	
\ ·	16	5,723,323		Kauffman et al.	03-03-1998	
	17	5,763,192		Kauffman et al.	06-09-1998	
	18	5,763,239		Short et al.	06-09-1998	
	19	5,770,434		Huse	06-23-1998	
	20	5,783,386		Jacobs, Jr. et al.	07-21-1998	
	21	5,789,228		Lam et al.	08-04-1998	
V	22	5,808,022		Huse	09-15-1998	
Hot,	23	5,811,238		Stemmer et al.	09-22-1998	

•			
Examiner	i _ i	Date	che la
Signature	T. Wundy	Considered	6/13/83

Complete if Known Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE TRADE Application Number 09/724,869 Fiffing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen **Group Art Unit** 1627 **Examiner Name** Unassigned (use as many sheets as necessary) Attorney Docket Number 02-030310US **Date Submitted** May 21, 2002

144)	24	5,814,473	 Warren et al.	09-29-1998		
1	25	5,814,476	Kauffman et al.	09-29-1998		
-	26	5,817,483	 Kauffman et al.	10-06-1998		
	27	5,824,469	Horwitz et al.	10-20-1998		
	28	5,824,514	Kauffman et al.	10-20-1998	DECEN/E	
	29	5,830,696	Short	11-03-1998	RECEIVE	
	30	5,830,721	Stemmer et al.	11-03-1998	JUN 1 0 2002	
	31	5,834,252.	Stemmer et al	11-10-1998	TECH CENTER 1600	20(
	32	5,837,458	Minshull et al.	11-17-1998	1ECH CENTER 1009	200
	33	5,862,514	Kauffman et al.	10-20-1998		
ı	34	5,866,344	Georgiou	02-02-1999	COPY OF PAPERS	
	35	5,866,363	Pieczenik	02-02-1999	UNIGINALLY FILE	J
	36	5,871,974	Huse	02-16-1999		*****
,	37	5,876,997	Kretz	03-02-1999		
	38	5,882,883	Egel-Mitani et al.	03-16-1999		
W	39	5,925,749	Mathur, et al.	07-20-1999		
Dot	40	5,928,905.	Stemmer et al	07-27-1999		
onfile	41	5,939,250	Short	08-17-1999		
Han	42	5,939,300	Robertson, et al.	08-17-1999		
γ	43	5,942,430	Robertson, et al.	08-24-1999		
1	44	5,948,666	Callen, et al.	09-07-1999		
	45	5,955,358	Huse	09-21-1999		
You pu	46	5,958,672	Short	09-28-1999		
tan	47	5,958,751	Murphy, et al.	09-28-1999		
+di	48	5,962,258	Mathur, et al.	10-05-1999		

			q	
Examiner	- · ·	Date		
Signature	T. Wiseyy	Considered	6/13/63	

	C C	omplete if Known	
	Application Number	09/724,869	
?	Anting Date	November 28, 2000	
	First Named Inventor	Juha Punnonen	
	Group Art Unit	1627	
	Examiner Name	Unassigned	
	Attorney Docket Number	02-030310US	
	Date Submitted	May 21 2002	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Withe	49	5,965,408	Short	10-12-1999	21-1077-N-76-1-07
The	50	5,962,283	Warren et al.	10-05-1999	
į	51	5,976,862	Kauffman et al.	11-02-1999	
1	52	5,985,285	Titball et al.	11-16-1999	RECEIVED
1	53	5,985,646	Murphy, et al.	11-16-1999	2002
V	54	5,989,553	Johnston, et al.	11-23-1999	IIIN U LOGE
North	55	6,001,574	Short et al.	12-14-1999	TECH CENTER 1600/290
1	56	6,004,788	Short	12-21-1999	1FOU AFTER
	57	6,030,779	Short	02-29-2000	
-this	58	6,043,030	Beach et al.	03-28-2000	COPY OF PAPERS
witer	59	6,054,267	Short	04-25-2000	ORIGINALLY FILED
Tav	60	6,054,312	Lacocca et al.	04-25-2000	
July	61	6,057,103	Short	12-21-1999	
Tour	62	6,087,341	Khavari et al.	07-11-2000	
1 1	62A	6,096,548	Stemmer	08-01-2000	
Cont	63	6,117,679	Stemmer	9-12-2000	
infu	64	6,132,970	Stemmer	10-17-2000	
400	65	6,153,410	Arnold et al.	11-28-2000	
1	66	6,156,511	Schatz et al.	12-05-2000	
	67	6,159,687	Vind	12-12-2000	
,	68	6,159,688	Borchert et al.	12-12-2000	
4/	69	6,165,718	Borchert et al.	12-26-2000	
NUT	70	6,165,793	Short	12-26-2000	
\sim	71	6,168,919	Short	01-02-2001	
	72	6,171,820	Short et al.	01-09-2001	

		[
Examiner		Date	
Signature	1. Vissey by	Considered	6/13/00
		1	L

Complete if Known

Application Number

O9/724,869

November 28, 2000

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

Date Submitted

Complete if Known

O9/724,869

November 28, 2000

Juha Punnonen

Unassigned

Unassigned

May 21, 2002

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Not	73	6,174,673	Short et al.	01-16-2001	
m	74	6,177,263	Arnold et al.	01-23-2001	RECEIVED
file	75	6,180,406	Stemmer et al.	01-30-2001	HE 1 0 2002
fre The	76	6,194,183	Markvardsen et al.	02-27-2001	JUN 1 0 DO DOL
1	77	6,238,884	Short et al.	05-29-2001	TECH CENTER 1600 290
	78	6,251,674	Tobin et al.	06-26-2001	1501,00
	79	6,261,561	Stewart, Jr. et al.	07-17-2001	
1	80	6,287,861	Stemmer et al.	09-11-2001	

				FOREIGI	N PATENT DOCUMEN	TS	
Exami ner Initials	Cite No.	Office	Foreign Patent Docu Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages T or Relevant Figures Appear
Tow	81	EP	0 125 228	A1	President and Fellows of Harvard College	06-15-1988	COPY OF PAPERS ORIGINALLY FILED
i	82	EP	0554809	B1	Ixsys, Inc.	12-16-1998	
	83	EP	0563296	B1	Ixsys, Inc.	03-17-1999	
(i)	84	EP	0 725081	A1	Kyowa Hakko Kogyo Co., Ltd.	08-07-1996	
	85	EP	0 752008	B2	Maxygen, Inc.	02-17-1995	
	86	EP	0876509	B1	Maxygen, Inc.	09-19-2001	
	87	EP	0911396	A2	Stemmer	04-28-1999	
	88	EP	0911396	A3	Stemmer et al.	05-06-1999	
	89	EP	0934999	A1	Stemmer et al.	08-11-1999	
	90	wo	90/14424		Scripps Clinic and Research	11-29-1990	

			q
Examiner Signature	T. Whendy	Date Considered	6/13/63

5 2002 S

Complete if Known Substitute for form 1449A-B/PTO **Application Number** 09/724,869 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen 1627 **Group Art Unit Examiner Name** Unassigned (use as many sheets as necessary) Attorney Docket Number 02-030310US May 21, 2002 **Date Submitted**

							10 1000
					Foundation		JUN 1
NW	91	wo	90/14443		Huse	11-29-1990	CENTERTO
1	92	wo	91/07979		Center for Innovative Technology	06-13-1991	TECH CENTER 100
1	93	wo	92/03461		lxsys, Inc.	03-05-1992	
,	94	wo	92/06176		lxsys, Inc.	04-16-1992	
	95	wo	92/06204		Ixsys, Inc.	04-16-1992	
	96	wo	92/11272		Ixsys, Inc	07-09-1992	
ı	97	wo	93/06214		The United States of America	04-01-1993	
1	98	wo	93/10214		Georgiou	05-27-1993	
	99	wo	94/06421		The University of Tennessee Research	03-31-1994	COPY OF PAPERS ORIGINALLY FILED
	100	WO	94/06911		Board of Regents, The University of Texas System	03-31-1994	
	101	wo	94/11496		Ixsys, Inc.	05-26-1994	
	102	WO	94/23738	A1	Medisorb Technologies International L.P.	10-27-1994	
	103	wo	94/25608		Baylor College of Medicine	11-10-1994	
	104	WO	94/26787	A1	The Boead of Trustees of the Leland Stanford Junior University	11-24-1994	
D. Wi	105ء	wo	95/22625		Stemmer et al.	08-24-1995	
tow	106	wo	95/16027	A1	Borrebaeck	06-15-1995	

			9
Examiner		Date	
Signature	T. Viscolo	Considered	6/13/23
			

JUN 0 5 2002 RE Filing Date
First Name Complete if Known Substitute for form 1449A-B/PTO plication Number 09/724,869 INFORMATION DISCLOSURE November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen 1627 Group Art Unit Unassigned **Examiner Name** (use as many sheets as necessary) 02-030310US **Attorney Docket Number Date Submitted** May 21, 2002

		_					11N 1 0 200
TOW	107	wo	95/26718		Apollon, Inc.	10-12-1995	-UTER 1600
1	108	WO	96/11279	A1	US Department of Health and Human Services	04-18-1996	JUN 1 0 2000 TECH CENTER 1600
1.	109	wo	96/13250	A1	Amgem, Inc.	05-09-1996	
	110	wo	96/23882		The Rockefeller University	08-08-1996	
1	111	wo	96/31613		Board of Regents	10-10-1996	
to fee	112	wo	96/33207		Glaxo Group Limited	10-24-1996	
100	113	wo	96/37624		MG-PMC, L.L.C.	11-28-1996	
fi	114	wo	97/04077		Recombinant Biocatalysis, Inc.	02-06-1997	
	115	wo	97/07128	A1	Duke University	02-27-1997	
,	116	wo	97/07205		Okkels	02-27-1997	
	117	wo	97/11605	A1	University of Pittsburg of the Commonwealth System of Higher Education	04-03-1997	COPY OF PAPERS ORIGINALLY FILED
19 Th	118	wo	97/20078		Stemmer et al.	06-05-1997	
taw	119	wo	97/25410		Borchert et al	07-17-1997	
Nin	120	wo	97/32987	A1	University of Toronto	09-12-1997	
4	121	wo	97/35957	A1	Stemmer	10-02-1997	
1	122	wo	97/35966		Maxygen Inc.	10-07-1997	
	123	wo	97/44361		Lam et al.	11-27-1997	
J	124	wo	97/48416		Mathur et al.	12-24-1997	
	125	wo	97/48717		Short et al.	12-24-1997	
V	126	wo	97/48794		Murphy et al.	12-24-1997	

		100		
Ì	Examiner	+ 14. 11	Date	(0/12/2
	Signature	· Went	Considered	11/03

Complete if Known Substitute for form 1449A-B/PTO **Application Number** 09/724,869 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen Group Art Unit 1627 Unassigned **Examiner Name** (use as many sheets as necessary) 02-030310US **Attorney Docket Number** May 21, 2002 **Date Submitted**

						-CEIVE
Then	127	wo	98/00526	Robertson et al.	01-08-1998	BECEIVED
1	128	wo	98/01581	Short	01-15-1998	JUN 1. 0 20 TECH CENTER 16001
1	129	wo	98/05764	Novo Nordisk	02-12-1998	CENTER 18001
1	130	wo	98/05765	Novo Nordisk	02-12-1998	TECHOEI
	131	wo	98/13485	Stemmer et al.	04-02-1998	
	132	wo	98/13487	Stemmer et al.	04-02-1998	
T	133	wo	98/24799	Bylina	06-11-1998	
	134	wo	98/27230	Patten et al.	06-25-1998	
	135	wo	98/28416	Bjornvad et al.	07-02-1998	
1	136	wo	98/31816	Regents of the University of Minnesota	07-23-1998	COPY OF PAPERS ORIGINALLY FILED
,	137	wo	98/31837	Delcardayre et al.	07-23-1998	
1	138	wo	98/36080	Affholter et al.	08-20-1998	
1.	139	wo	98/41622	Borchert et al.	09-24-1998	
	140	wo	98/41623	Borchert et al.	09-24-1998	
V	141	wo	98/41653	Vind et al.	09-24-1998	
18/ju	-142	wo	98/42727	SRI International	10-01-1998	
trali	143	wo	98/42832	Arnold et al.	10-01-1998	
i	144	wo	98/45444	The Regents of the University of California	10-15-1998	
-	145	wo	98/48034	Neiboer et al.	10-29-1998	
	146	wo	98/49286	Board of Regents, The University of Texas System	11-05-1998	
W	147	wo	98/58085	Short et al.	12-23-1998	

	[}
Examiner	Date	
Signature	Considered	

JUN 0 5 2002 By

Application
First Name

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	₽ Co	omplete if Known	
	Application Number	09/724,869	
n	- ∰ing Date	November 28, 2000	
_	First Named Inventor	Juha Punnonen	
	Group Art Unit	1627	
	Examiner Name	Unassigned	
	Attorney Docket Number	02-030310US	
	Date Submitted	May 21, 2002	٦

			· · · · · · · · · · · · · · · · · · ·		1	
tiv	148	wo	99/07837	Callen	02-18-1999	CEIVEY
1	149	wo	99/08539	Kretz	02-25-1999	HEO2
	150	wo	99/10472	Short	03-04-1999	RECEIVED
	151	wo	99/10539	Short	03-04-1999	TECH CENTER 1600
1.	152	wo	99/19506	ixsys, inc.	04-22-1999	TECH OF !
1	154	wo	99/19518	Short	04-22-1999	
,	155	wo	99/21979	Apt et al.	05-06-1999	
	156	wo	99/23107	Stemmer et al.	05-14-1999	
	157	wo	99/23236	Diversa Corp. et al.	05-14-1999	
	158	wo	99/29902	Arnold et al.	06-17-1999	
	159	wo	99/41366	The Board of Trustees of the Leland Stanford Junior University	08-19-1999	COPY OF PAPERS ORIGINALLY FILED
1.	160	wo	99/41368	Maxygen, Inc.	08-19-1999	
	161	wo	99/41369	Maxygen, Inc.	08-19-1999	
	162	wo	99/41383	Maxygen, Inc.	08-19-1999	
	163	wo	99/41402	Maxygen, Inc.	08-19-1999	
	164	wo	99/45154	Short et al.	09-10-1999	
	165	wo	99/57128	Stemmer et al.	11-11-1999	
-	166	wo	99/65927	Maxygen, Inc,	12-23-1999	
	167	wo	00/18778	Phylos, Inc.	04-06-2000	
	168	wo	00/42560	Selifonov et al.	07-20-2000	
-	169	wo	00/42561	Crameri et al.	07-20-2000	
	170	wo	00/46344	Diversa Corrporation	08-10-2000	
4	171	wo	00/53744	Short et al.	09-14-2000	

			9
Examiner		Date	
Signature	T. Wend	Considered	6/13/13
<u> </u>	· // // // // // // // // // // // // //		·/

Macient Substitute for form 1449A-B/PTO Complete if Known **Application Number** 09/724,869 INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor Juha Punnonen **Group Art Unit** 1627 **Examiner Name** Unassigned (use as many sheets as necessary) **Attorney Docket Number** 02-030310US **Date Submitted** May 21, 2002

172	wo	00/58517	Short et al.	10-05-2000	JUN 7 3 1 400 2900
173	wo	00/16984	Maxygen, Inc	03-30-2000	TECH CENTER 1800/2900
174	wo	01/00234	Maxygen, Inc	01-04-2001	
					COPY OF PAPERS ORIGINALLY FILED

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Exami ner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т
thw	175	Affholter et al. (1998) "Directed evolution of proteins and pathways by DNA shuffling." Book of Adstracts, 216th ACS National Meeting, Boston, August 23-27, BIOT-042	
)	176	Agren et al. (1997) "Genetically Engineered Nontoxic Vaccine Adjuvant That Combines B Cell Targeting with Immunomodulation by Cholera Toxin A1 Subunit." J. Immunol 158:3936	
	177	Ahmed (1995) J Bacteriology 177(14):3904-3910	
1	178	Ahn et al. (1996) "Human cytomegalovirus inhibits antigen presentation by a sequential multistep process." <i>Proc. Natl. Acad, Sci USA</i> 93:10990	
].	179	Aizaki et al. (1998) "Full-Length Complementary DNA of Hepatitus C Virus Genome From an Infectious Blood Sample." Hepatology 27:621-627 (1998)	
1.	180	Aldovini & Young (1991) "Humoral and cell-mediated immune response to live recombinant BCG-HIV vaccines." Nature 351:479-482	
	181	Ambriovic, A. et al. (1997) "Efficacy of Replication-Defective Adenovirus-Vectored Vaccines: Protection Following Intramuscular Injection Is Linked to Promoter Efficiency in Muscle Representative Cells" Virology 238:, 327-335	
	182	Appel and Harris (1998) "Antiboby titers in domestic ferret fills and kits to canine distemper virus vaccines." <i>JAVMA</i> 193:332-333	
-	183	Atkins et al. (1996) "Manipulation of the Semliki Forest Virus Genome and Its Potential for Vaccine Construction." <i>Mol Biotechnol</i> 5:33-38	
\	184	Attridge et al. (1997) "Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain." Vaccine 15(2): 155-162	
V	185	Axon (1998) "Treatment of Helicobacter pylori: future therapeutic and prophylactic perspectives." Gut 43(1):S70-3	
Sari	₂ 186	Baba et al., "Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC," The J. of Biolog. Chem. 272 (23): 14893-14898 (1997)	
tow	187	Barry et al. (1994) "Production of monoclonal antibodies by genetic immunization." Short Technical Reports in Biotechniques 16(4):616	
-72h	188	Barry et al. (1995) "Protection against nycoplasma infection using expression-library immunization." Nature 377:632	

			,
Examiner	T 101 : 11	Date	6/12/2
Signature	T. Wenny	Considered	117/09

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Application Date Complete if Known Application Number 09/724,869 November 28, 2000 First Named Inventor **Juha Punnonen Group Art Unit** 1627 Unassigned **Examiner Name** 02-030310US **Attorney Docket Number Date Submitted** May 21, 2002

(use as many sheets as necessary)

thin	189	Bass et al. (1990) "Hormone Phage: An Enrichment Method for Variant Proteins With Altered Binding Properties." <i>Proteins: Structures, Function and Genetice</i> 8:309-314
pot	190	Beattie et al. (1990) "Cloning and characterization of T-cell-reactive protein anigens from Listeria monocytogenes." Infection and Immunity 58(9):2792-2803
fri Tiv	191	Beck et al., "DNA Sequence Analysis of 66 kb of the Human MHC Class II Region Encoding a Cluster of Genes for Antigen Processing," J. Mol. Biol. 228:433-441 (1992)
riv	192	Behrens et al. (1996) "Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus." <i>EMBO J.</i> 15:12-22
1	193	Benham et al. (1997) "Proteasome activity limits the assembly f HMC class 1 molecules after IFN-gamma stimulation." <i>J. Immol</i> 159(2):5896-5904
`\	194	Berkhout et al. (1999) "Genetic Instability of Live, Attenuated Human Immunodeficiency Virus Type I Vaccine Strains." J. Virology 73(2):1138-1145
	195	Bernard et al. (1994) "Transcriptional Control and Cell Type Specificity of HPV Gene Expression." Arch Dermatol 130:210
1	196	Bhatnagar et al. (1982) "Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the a determinant." <i>Proc Nat'l Acad Sci USA</i> 79:4400-4404
· 1	197	Bielefeldt-Ohmann, H. et al., "Analysis of a recombinant dengue-2 virus-dengue-3 virus hybrid envelope protein expressed in a secretory baculovirus system," J. Gen. Virol. 78:2723-2733 (1997)
Jan Jan	198	Blachere et al., "Heat Shock Protein-Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphyocyte Response and Tumor Immunity," J. Exp. Med. 186:1315-22 (1997
TOW 199		Blanchard et al. (1998) "Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins" J. Gen. Virol 79:1159-1167
4	200	Blaser (1998) "Helicobacter pylori and gastric disease." BMJ 316:1507-1510
	201	Bloom et al. (1993) Characterization of Chimeric Full-Length Molecular Clones of Aleutian Mink Disease Parvovirus (ADV)* <i>J. Virol</i> 67(10):5976-5988
V	202	Bolhuis (1995) J. Biological Chamistry 270(3):26092-26098
migh	203	Botstein and Shortle, "Strategies and Applications of in Vitro Mutagenesis," Science 229:1193-1201 (1985)
1546	204	Boursnell et al. (1997) "A Genetically Inactivated Herpes Simplex Virus Type 2 (Hsv-2) Vaccine Provides Effective Protection against Primary & Recurrent HSV-2 Disease." J. Infect. Dis 175:16-25
-	205	Bray et al. (1989) "Mice Immunized with Recombinant Vaccinia Virus Expressing Dengus Virus Encepha;it is." <i>J. Virol</i> 63:2853-2856
-	206	Bridgen and Elliot (1996) "Rescue of a segmented negative-strand RNA virus entirely from cloned complementary DNA's." <i>Proc. Nat'l Acad. Sci USA</i> 93:15400-15404
	207	Brocke et al. (1996) "Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein." <i>Nature</i> 379:343-346
	208	Brubaker (1991) "The V Antigen of Yersiniae: An Overview." Current Investigations of the Microbiology of Yersinae 12:127-133
I	209	Burger et al. (1995) Proc. of thr Amer Assoc. for Cancer Research 36:522 Abst #3108
V	210	Burke et al. (1999) "Formulation, Stability and Delivery of Live Attenuated Vaccines for Human Use." Crit. Rev. Ther Drig. Carrier Syst 16:1-83
Exam	inor	Data /
⊏xam	iii ier	Date /a/is/on

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Weary

Signature

Considered

May 21, 2002

Pan Application Number Substitute for form 1449A-B/PTO Complete if Known 09/724,869 November 28, 2000 INFORMATION DISCLOSURE STATEMENT BY APPLICANT First Named Inventor **Juha Punnonen** Group Art Unit 1627 **Examiner Name** Unassigned (use as many sheets as necessary) 02-030310US **Attorney Docket Number**

Date Submitted

- HOW	211	Burton (1995) "Phage Display." Immunotechnology 1(2):87-94
+021	212	Carroll and Moss (1997) "Host range and Cytopathogenicity of the Highly Attenuated MVA Strain of Vaccinia Virus" Virology 238:198-211
Net	213	Carter et al., "Improved oligonucleotide site-directed mutagenesis using M13 vectors," Nucl. Acids Res. 13:4431-4443 (1985)
9m	214	Carter, "Improved Oligonucleotide-Directed Mutagenesis Using M13 Vectors," Methods in Enzymol. 154:382-403 (1987)
file	215	Carter, "Site-directed mutagenesis," Biochem. J. 237:1-7 (1986)
fair	216	Casal (1999) "Use of parvovirus-like particles for vacation and induction of multiple immune response." Biotechnol Appl. Biochem 29:-141-150
fdin	217	Cathomen et al. (1998) "A matrix-less measles virus is infectious and extensive cell fusion: consequences for propagation in the brain." <i>EMBO J.</i> 17(14):3899-3908
300	218	Chang, C., et al. (1999) "Evolution of a cytokine using DNA family shuffling." Nature Biotechnology 17:793-797.
-falli	219	Chen et al. "Regulatory T Cell Clones Induced by Oral Tolerance: Suppression of Autoimmune Encephalomyelitis." Science 265:1237-1240
201	220	Chen et al., "Discontinuous epitopes of hepatitis B surface antigen derived from a filamentous phase peptide library," Proc. Nat'l. Acad. Sci. USA 93:1997-2001 (1996)
tall	221	Chin et al. (1993) "Functions and Regulation of the Human Miltidrug Resistance Gene." Adv. Cancer Res. 60:157-180
ti	222	Choate and Khavari (1997) "Sustainability of Keratinocyte Gene Transfer and Cell Survival In Vivo." Human Gene Therapy 8:895-901
2/2	223	Christians, F.C. et al., "Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling," Nature Biotechnology 17:259-264 (1999)
tal	224	Chu et al. (1995) "A Vaccina Virus-Vectored Hantaan Virus Vaccing Protects Hamsters from Challenge with Hantaan and Seoul Viruses but Not Pumala Virus." J. Virol 69:6417
.—	225	Clackson et al. (1994) "In vitro selection from protein and peptide libraries." <i>Trends Biotechnol</i> 12(5): 173-184
	226	Coco et al., (2001) "DNA shuffling method for generating highly recombined genes and evolved enzymes" Nature Biotechnology vol. 19 pp. 354-359
1	227	Collman et al. (1992) "An Infectious Molecular Clone of an Unusual Macrophage-Tropic and Highly Cytopathic Strain of Human Immunodeficiency Virus Type 1." <i>J. Virol</i> 66(12):7517-7521
-	228	Conry et al. (1996) "Selected strategies to augment polynucleotide immunization." Gene Therapy 3(1):67-74
	229	Conry et al. (1994) "Immune response to a carinoembryonic antigen polynucleotide vassine." Cancer Res. 54:1164-1168
	230	Coppel et al. (1993) "idenification of a coda clone encoding a mature blood stage antigen of Plasmodium falciparum by immunization of mice with bacterial lysates." <i>EMBO Journal</i> 3)2):403-407
J	231	Cote et al. (1986) "Protection of Chimpanzees from Type B Hepatitis by Immunization with Woodchuck Hepatitis Virus Surface Antigen." <i>J. Virol</i> 60:895-901
Dan't	232	Courvalin et al. (1995) "Gene transfer from bacteria to mammalian cells." C.R. Acad. Sci III 18:1207-
٧		4
Exam	iner	To West Considered C/12/03
Signa	ıture	T. Warred 6/12/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

0 5 2002 H

BRATE PAGE Complete if Known Substitute for form 1449A-B/PTO 09/724,869 Application Number INFORMATION DISCLOSURE Filing Date November 28, 2000 STATEMENT BY APPLICANT First Named Inventor **Juha Punnonen** Group Art Unit 1627 Unassigned **Examiner Name** (use as many sheets as necessary) 02-030310US Attorney Docket Number **Date Submitted** May 21, 2002

	Ι	1212
<u> </u>		
-Til	233	Crabtree (1998) "Eradication of chronic Helicobacter pylori infection by therapeutic vaccination." <i>Gut</i> 43:7-8
Kin	234	Craiu et al., "Two distinct proteolytic processes in the generation of a major histocompatibility complex class i-presented peptide," Proc. Nat'l. Acad. Sci. USA 94:10850-10855 (1997
1000	235	Crameri & Stemmer (1993) "10(20)-fold aptamer library amplification without gel purification." Nucleic Acids Research 21(18): 4410
NOT	u ²³⁶	Crameri, A. et al., "Combinatorial Multiple Cassette Mutagenesis Creates All the Permutations of Mutant and Wild-Type Sequences," Biotechniques 18:194-195 (1995)
7	237	Crameri, A. et al., "Construction and evolution of antibody-phage libraries by DNA shuffling," Nature Medicine 2:100-103 (1996)
1	238	Crameri, A. et al., "DNA shuffling of a family of genes from diverse species accelerates directed evolution," Nature 391:288-291 (1998) (2-287-1PC & 2-251PC)
7.	239	Crameri, A. et al., "Improved Green Fluorescent Protein by Molecular Evolution Using DNA Shuffling," Nature Biotechnology 14:315-319 (1996)
1	240	Crameri, A. et al., "Molecular evolution of an arsenate detoxification pathway by DNA shuffling," Nature Biotechnology 15:436-438 (1997)
1	241	Cresswell & Hughes, "Protein degradation: The ins and outs of of the matter," Curr. Biol. 7:R552-R555 (1997)
Men	242	Cwirla et al. (1990) "Peptides on Phage: A vast library of peptides for identifying ligands." <i>Proc. Nat'l Acad Sci USA</i> 87:6378-6382
	243	Davis et al (1995) "DNA-based immunization." Molecular and Cell Biology of Human Gene Therapeutics 5:368-387
q	245	Davis et al. (1989) "In vitro Synthesis of Infectious Venezuelar Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant." <i>Virology</i> 171:189-204
	246	Davis et al. (1997) "DNA-Based immunization against hepatitis B surface antigen (HBsAg) in Normal and HBsAg-transgenic mice." <i>Vaccine</i> 15(8) 849-822
	247	Deng et al. (1997) "Sustainable cutaneous gene delivery." Nature Biotechnol 15:1388-1391
J	248	Devlin et al. (1990) "Random Peptide Libraries: A Source of Specific Protein Binding Molecules." Science 249:404-406
is of	L249	Dieu et al., "Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites," J. Exp. Med. 188:373-386 (1998)
tree	, 250	DiMarco et al. (1997) "Agnostic and antagonistic variants of ciliary neurothrophic Factor (CNTF) Reveal functional differences between mambrean-bound and soluble CNTF Alpha-receptors." <i>J Biol. Chem.</i> 272(37):23069-23075
Ą	251	Donovan et al. (1987) "Genes Encoding Spore Coat Polypeptides from Bacillus subtilis." J. Mol Biol 196:1-10
1.	252	Drabkin et al. (1996) "Amber Suppression in Mammalian Cells Dependent upon Expression of an Escherichia coli Aminoacyl-tRNA Synthetase Gene." <i>Mol Cell. Biol.</i> 16(3):907-913
	253	Dubols et al. (1998) "Immunization against Natural Helicobacter pylori Infection in Nonhuman Primates." Infect. Immun. 66:4340-4346
		·

Examiner		1.7. 1		Date	<i>(1)</i>		
Signature	7.	Wurd	7)	Considered	4/11	105	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO
INFORMATION DISCLOSURE
PADE TO A PRI ICANT Complete if Known 09/724,869 Application Number November 28, 2000 Ming Date STATEMENT BY APPLICANT First Named Inventor Juha Punnonen 2002 0 1 NUL **Group Art Unit** 1627 **Examiner Name** Unassigned ECH CENTER 1600/2900 (use as many sheets as necessary) Attorney Docket Number 02-030310US **Date Submitted** May 21, 2002

9	254	Dunn (1996) "Phage display of proteins." Curr Opin Biotechnology 7(5):547-553
1	255	Eghtedarzadeh and Henikoff, "Use of oligonucleotides to generate large deletions," Nucl. Acids Res. 14:5115 (1986)
1	256	Engels and Ackermann (1996) "Pathogenesis of ruminant herpesvirus infections." Vet Microbiol 53:3-
í	257	Felici, Franco et al., "Peptide and protein display on the surface of filamentous bacteriophage," Biotechnol. Annu. Rev. 1:149-83 (1995)
(258	Fields et al., "Crystal structure of a T-cell receptor B-chain complexed with a superantigen," Nature 384:188-192 (1996)
,	259	Fox et al. (1996) "Anaerobic bacteria as a delivery system for cancer gene therapy: In vitro activation of 5-fluorocytosine by genetically engineered clostridia." Gene Ther 3:173-178
•	260	Francisco, Joseph A. et al., "Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface," Proc. Nat'l. Acad. Sci. USA 90:10444-10448 (1993)
	261	Frankel and Young (1998) "HIV-1 Fifteen Proteins and an RNA." Annu. Rev. Biochem 67:1-25
?	262	Freeman et al., "B7-1 and B7-2 Do Not Deliver Identical Costimulatory Signals, Since B7-2 but Not B7-1 Preferentially Costimulates the Initial Production of IL-4," Immunity 2:523 (1995)
•	263	Fritz et al. "Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro," Nucl. Acids Res. 16:6987-6999 (1988)
7.	264	Fritz et al. "Oligonucleotide-directed construction of mutations: a gapped duplex DNA procedure without enzymatic reactions in vitro," Nucl. Acids Res. 16:6987-6999 (1988)
7	265	Gaczynska et al.,"Proteasome Subunits X and Y alter Peptidase Activities in Opposite Ways to the Interferon-γ-induced Subunits LMP2 and LMP7*, J. Biol. Chem. 271:17275-17280 (1996)
•	266	Galler et al. (1997) "The Yellow fever 17D vaccine virus: molecular basis of viral attnuation and its use as an expression vector." <i>J. Med Biol. Res.</i> 30:157-168
1	267	Galocha et al. (1997) "The Active Site of ICP47, a Herpes Simple Virus-encoded Inhibitor of the Major Histocompatibility Complex " J. Exp. Med 185:1565-1572
١	268	Garnett and Grenfell (1992) "The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster." <i>Epidemiol. Infect</i> 108:513-528
τ,	269	Gates, C.M. et al., "Affinity Selective Isolation of Ligands from Peptide Libraries Through Display on a lac Repressor 'Headpiece Dimer" J. Mol. Biol. 255:1-14 (1996)
•	270	Geigenmuller et al. (1997) "Construction of a Genome-Length cDNA Clone for Human Astrovirus Serotype 1 and Synthesis of Infectious RNA Transcrips." <i>J. Virol</i> 71:1713-1717
ı	271	Goldman et al. (1999) Molecular Cloning and Expression of Major Structural Protein" <i>J. Virol.</i> 73:4465-4469
,	272	Gritsun et al. (1998) "Development and analysis of a tick-bone encephalitis virus infectious clone using a novel and rapid strategy." J Virol. Methods 76:109-120
1	273	Groettrup et al. "The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome," Proc. Nat'l. Acad. Sci. USA 94:8970-8975 (1997)
7	274	Groettrup et al., "A third interferon –γ-induced subunit exchange in the 20S proteasome," Eur. J. Immunol. 26:863-869 (1997)
	·	· · · · · · · · · · · · · · · · · · ·

	(
Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 0 5 2002 HIJ

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	omplete if Known	
Application Number	09/724,869 PECELVE	
Filing Date	November 28, 2000	
First Named Inventor	Juha Punnonen JUN 1 0 2002	
Group Art Unit	1627 JOIN 1 0 2002	
Examiner Name	Unassigned TEQUARATED 4000	0000
Attorney Docket Number	02-030310US TECH CENTER 1600/	2900
Date Submitted	May 21, 2002	

MAT	275	Groux et al.,"A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis," Nature 389:737 (1997)			
file	276	Grundstrom et al., "Oligonucleotide-directed mutagenesis by microscale 'shot-gun' gene synthesis," "Nucleic Acids Res. 13:3305-3316 (1985)			
TW 277		Gualano et al. (1998) "Identification of a major determinant of mouse neurovirulence of dengue virus typw 2 using stably cloned genomic-length cDNA." <i>J. Gen. Virol.</i> 79:437-466			
	278	Guo et al. (1998) "Susceptibility to recombination rearrangements of a chimeric plum pox potyvirus genome after insertion of a foreign gene." <i>Virus Res</i> 57:183-195			
1	279	Halminen et al. (1997) "Expression of MXA Protein in Blood Lymphocytes Discriminates between Viral and Bacterial Infections in Febrile Children." <i>Pediatric Research</i> 41:647-650			
	280	Han, Xiaoliang et al., "Ligand-directed retroviral targeting of human breast cancer cells," Proc. Natl. Acad. Sci USA 92:9747-9751 (1995)			
1	281	Hanes, Jozef and Andreas Pluckthun., "In vitro selection and evolution of functional proteins by using ribosome display," Proc. Nat'l. Acad. Sci. USA 94(10):4937-42 (1997)			
A	282	Haq et al. (1995) *Oral Immunization with a Recombinant Bacterial Antigen Produced in Transgenic Plants." Science 268:714-716			
ı	283	Haralambiev (1967) "Immunogenicity Studies on a Inactivated IBR Vaccine Administered Into the Nasal Mucosa." Acta Vet Acad Sci Hung 26:215-217			
	284	Harrington et al. (1992) "An outbreak of Respiratory Syncytial Virus in a Bone Marrow Transplant Center." J. Infect Dis. 165:987-993			
	285	HCJ Ertl et al., (1996) "Genetic Immunization" Viral Immunization Vol. 9, No. 1, pp. 1-9.			
\(\)	286	He et al., "Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites," Nucl. Acids Res. 25(24):5132-4 (1997)			
•	287	He et al. (1998) "The Paramyxovirus SV5 Small Hydrobhobic (SH) Protein Is Not Essential for Virus Growth in Tissue Culture Cells." <i>Virology</i> 250:30-40			
,	288	Hedstrom et al. (1994) "Prospects and strategies for development of DNA vaccines against malaria." 59th Forum in Immunology 476-482			
\ \	289	Hensel and Lubitz (1997) Vaccination by Aerosols: Modulation of Clearance Mechanism in the Lung." Behring. Inst. Mitt. 98:212-219			
	290	Hilgers et al. (1990) "Caco-2 Cell Monolayers as a Model for Drug Transport Across the Intestional Mucosa." Pharmaceutical Res. 7(9):902-910			
,	291	Hill et al., "Phage presentation," Mol Microbiol 20(4):685-92 (1996)			
	292	Hoffman and Banerjee (1997) "An Infectious Clone of Human Parainfluenza Virus Type 3." <i>J Virol.</i> 71:4272-4277			
\	293	Hohol et al. (1996) "Three-year Open Protocol Continuation Study of Oral Tolerization with Myelin Antigens in Multiple Sclerosis and Design of a phase III Pivotal Trial." Ann. N.Y. Acad Sci. 778:243-250			
$\overline{}$	294	Holzmann, H. et al., "Molecular epidemiology of tick-bome encephalitis virus: cross-protection between European and Far Eastern subtypes," Vaccine 10:345 (1992)			
	295	Hopkins and Yoder (1986) "Reversion to Virulence of Chicken-Passaged Infectious Bronchitis Vaccine Virus." Avain Dis. 30:221-223			
\L	296	Hourvitz et al. (1996) "Reactogenicity and immunogenicity of a new recombinant hepatitis B Vaccine			
Examiner Date		Date			
Signature Considered		Considered			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

72		<u> </u>	
13	C C	omplete if Known	
W. m	Application Number	09/724,869	_
A	Application Number Filing Date	November 28, 2000 HHCH	10
	First Named Inventor	Juha Punnonen	
	Group Art Unit	1627 JUN 1 0 2002	
	Examiner Name	Unassigned	
v)	Attorney Docket Number	02-030310US TECH CENTER 1600	loor
	Date Submitted	May 21, 2002	23(

(use as many sheets as necessary)

		containing Pre S Antigens." J Virol. Hepatitis 3:37-42			
.	Howard (1998) "Chemistry of the future: Exploitation of the power of biology." Book of Abstracts, 216th				
Tan	ACS National Meeting, Boston, August 23-27, BTEC-045 Apst #: 528494				
~.	298	Hristov and Karadjov (1975) Vet Med Nauki 13:5			
<u> </u>	299	Huang, Sharon K.S. et al., "Antibody Responses to Melanoma/Melanocyte Autoantigens in Melanoma			
\rightarrow	233	Patients," J. Invest. Dermatol. 111:662-7 (1998)			
	300	Hui, George S.N. et al., "Dominance of Conserved B-Cell Epitopes of the Plasmodium falciparum			
\ \		Merozoite Surface Protein, MSP1, in Blood-Stage Infections of Naïve Actus Monkeys," Infect. Immun. 64:1502-1509 (1996)			
•	301	Hulskotte at al. (1998) "Towards an HIV-1 vaccine: lessons from studies in macaque models." Vaccine 16:904-915			
	302	Hurtado et al. (1996) "Identification of Domains in Canine Parvovirus VP2 Essential for the Accembly of Virus-Like Particles." J. Virol 70:5422-5429			
V	303	lacono-Connors et al., Virus Res. 43:125-136 (1996)			
12 Miles	304	Irvine, K.R. et al., "Cytokine Enhancement of DNA Immunization Leads to Effective Treatment of Established Pulmonary Metastases," Journal of Immunology, 156:238-245 (1996)			
you	305	Jia et al. (1995) "A Novel virant of avain infectious bronchitis virus resulting from recombination among three different strains." <i>Arch Virol</i> 140:259-271			
ſ	306	Jiang et al. (1999) "Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles." Vaccine 17:1005-1013			
	307	Jiang et al., "Subtraction hybridization identified a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression," Oncogene 11:2477 (1995)			
	308	Jiang et al., "The melanoma differentiation associated gene mda-7 suppresses cancer cell growth," Proc. Nat'l. Acad. Sci. USA 93:9160 (1996)			
	309	Jin et al. (1998) "Recombinant Human Respiratory Synctial Virus (RSV) from cDNA and Construction of Subgroup A and B Chimeric RSV." Virology 251:206-214			
1	310	Johnston, et al. (1997) "Genetic to genomic vaccination" Vol. 15, no. 8 pp 808-809			
7	311	Kang et al. (1999) "Development of HIV/AIDS Vaccine Using Chimeric gag-env Virus-like Particles." Biol. Chem 380:353-364			
	312	Karandikar et al.,"CTLA-4: A Negative Regulator of Autoimmune Disease," J. Exp. Med. 184:783 (1996)			
•	313	Keck. Et al. (1988) "In Vivo RNA-RNA Recombination of Coronavirus in Mouse Brain." <i>J. Virol.</i> 62:1810-1813			
•	314	Keenan et al.,"Lack of Protection following immunisation with H. pylori outer membrane vesicles highlights antigenic differences between H. felis and H. pylori," FEMS Microbiol Lett. 161:21-7 (1998)			
•	315	Khavari, (1997) " Therapeutic gene delivery to the skin" Molecular Medicine Today, Dec. 1997: 533538			
•	316	Khavari and Krueger (1997) "Cutaneous Gene Therapy." Adv Clin Res Dermatologic Clinics 15(1): 27-35			
V	317	Khusmith et al. (1991) "Protection against malaria by vaccination with sporozoite surface protein 2 plus			
		1			
Exami	iner	Date			
Signat	ture	Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

0 5 2002

Substitute for form 1449A-B/PTO		omplete if Known	
TRADEN	Application Number	09/724,869	
INFORMATION DISCLOSURE	Filing Date	November 28, 2000 DECEIVE	
STATEMENT BY APPLICANT	First Named Inventor	Juha Punnonen ILLULIVI	. U
	Group Art Unit	1627	
	Examiner Name	Unassigned JUN (0 2002	
(use as many sheets as necessary)	Attorney Docket Number	02-030310US	
	Date Submitted	May 21, 2002 TECH CENTER 1600/	2900

318 Kim et al., "In Vivo Engineering of a Cellular Immune Response by Coadministration of IL-12 Expression Vector with a DNA Immunogen," J. Immunol. 158:816 (1997) 319 Kim, et al. (1997) "Development of a multicomponent candidate vaccine for HIV-1" Vaccine, Vol. 15 No. 8 pp 879-883. 320 Kinney et al. (1997) "Construction of Infectious cDNA Clones for Dengue 2 Virus: Strain 16881 and Its Attenuated Vaccine Derivative, Strain PDK-53." Virology 230:300-308 Kinney et al., "Poerombinant Vaccine in Virus Renezuelan Equine Encephalitis (VEE) Virus Protects Mice from Peripheral VEE Virus Challenge," J. Virol. 62:4697 (1998) Kinney et al., "Vaccine development against infection with Helicobacter pylori," Br. Med. Bull. 54:229-41 (1998) Kilman et al., "Copf motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon D." Proc. Natl. Acad. Sci. USA 93:2879 (1996) Kobayashi et al., "Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) Kobayashi, Vuzuru et al., "Antipolic Analysis of Japanese Encephalitis Virus by Using Monoclonal Antibodies," Infect. Immun. 44:117 (1984) Kochel, Tadeusz et al., "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," Vaccine 15:547-552 (1997) 239 Kodama et al., "Type I macrophage scavenger receptor contains -helical and collagen-like coiled coils," Nature 34:3531-535 (1990) 240 Kompan et al., "Generation, intracellular transport and loading of peptides associated with MHC class 1 molecules," Curr. Opin. Immunol. 9:80-88 (1997) 241 Kramer et al., "Generation, intracellular transport and loading of peptides associated with MHC class 1 molecules," Curr. Opin. Immunol. 9:80-88 (1997) 242 Kramer et al., "Generation, intracellular transport and loading of peptides associated with MHC class 1 molecules," Curr. Opin. Immunol. 9:80-88 (1997) 243 Kramer et al., "Type			CS protein." Science 252:715	
Expression Vector with a DNA immunogen," J. Immunol. 158:816 (1997) Stime et al. (1997) "Development of a multicomponent candidate vaccine for HIV-1" Vaccine, Vol. 15 No. 8 pp 879-883. Stime et al. (1997) "Construction of Infectious cDNA Clones for Dengue 2 Virus: Strain 16681 and Its Attenuated Vaccine Derivative, Strain PDK-53." Virology 230:300-308 Stime et al., "Recombinant Vaccinia Virus/Benezuelan Equine Encephalitis (VEE) Virus Protects Mice from Peripheral VEE Virus Challenge," J. Virol. 62:4697 (1998) Stime et al., "Vaccine development against infection with Helicobacter pylori," Br. Med. Bull. 54:229-41 (1998) Stimen et al., "CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6; interleukin 12 and interferon 0." Proc. Nat'l. Acad. Sci. USA 93:2879 (1996) Stimen et al., "Contribution of CpG Motifs to the Immunopenicity of DNA Vaccines," Journal of Immunology, 158:3635-3639 (1997) Kobayashi et al.,"Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1999) Kobyashi, Yuzuru et al., "Antigenic Analysis of Japanese Encephalitis Virus by Using Monoclonal Antibodies," Infect. Immun. 44:117 (1984) Kochel, Tadeusz et al., "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," Vaccine 15:547-552 (1997) Stome et al., "Poly Imacrophage scavenger receptor contains -helical and collagen-like coiled coils," Nature 343:531-535 (1990) Stome et al., "Poly Imacrophage scavenger receptor contains -helical and collagen-like coiled coils," Nature 343:531-535 (1992) Konjahi et al., "A Highly Attentuated Host Range-Restricted Vaccinia Virus Strain, NYVAC, Encoding the prift, E and NS1 Genes of Japanese Encephalitis Virus Prevents JEV Viremia in Swine," Virology 190:454 (1992) Konjahi et al., "Generation, intracellular transport and loading of peptides associated with MHC class 1 molecules," Curr. Opin.	1 100			
319 Kim, et al. (1997) "Development of a multicomponent candidate vaccine for HIV-1" Vaccine, Vol. 15 No. 8 pp 879-883. Kinney et al. (1997) "Construction of Infectious cDNA Clones for Dengue 2 Virus: Strain 16681 and Its Attenuated Vaccine Derivative, Strain PDK-53. *Virology 230:300-308* Kinney et al. (1997) "Construction of Infectious cDNA Clones for Dengue 2 Virus: Strain 16681 and Its Attenuated Vaccine Derivative, Strain PDK-53. *Virology 230:300-308* Kinney et al. (1997) "Construction of Infectious cDNA Clones for Dengue 2 Virus: Strain 16681 and Its Attenuated Vaccine Derivative, Strain PDK-53. *Virology 230:300-308* Kinney et al. (1998) "Construction of Infectious cDNA (1998) "Construction of Matural Killer Cell Stimulatory Fig. Med. Bull. 54:229-41 (1998) "Construction of CpG Motifs to the Immunogenicity of DNA Vaccines," Journal of Immunology, 158:3635-3639 (1997) "Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) "Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) "Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) "Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) "Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) "Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) "Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) "Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) "Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) "Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) "Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) "Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) "Cytokine with Multiple Biologic Effects an Human		318		
Kinney et al., "Necombinant Vaccinia Virus/Benezuelan Euclen Euclen Encephalitis (VEE) Virus Protects Mice from Peripheral VEE Virus Challenge," J. Virol. 62:4697 (1998)	- Nielu	1	Kim, et al. (1997) "Development of a multicomponent candidate vaccine for HIV-1" Vaccine, Vol. 15 No.	
## Ainney et al., "Hecombinant Vaccina Virus/Benezuelan Equine Encephalitis (VEE) Virus Protects Mice from Peripheral VEE Virus Challenge," J. Virol. 62:4697 (1998) ## 322 Kleanthous et al., "Vaccine development against infection with Helicobacter pylori," Br. Med. Bull. 54:229-41 (1998) Klimman et al., "Copf motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12 and interferon □," Proc. Nat'l. Acad. Sci. USA 93:2879 (1996) Klimman, D.M. et al., "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," Journal of Immunology, 158:3635-3639 (1997) Kobayashi et al., "Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) Kobayashi, Yuzuru et al., "Antigenic Analysis of Japanese Encephalitis Virus by Using Monoclonal Antibodies," Infect. Immun. 44:117 (1984) Kodame et al., "Type I macrophage scavenger receptor contains -helical and collagen-like coiled coils," Nature 343:531-535 (1990) Kodame et al., "Type I macrophage scavenger receptor contains -helical and collagen-like coiled coils," Nature 343:531-535 (1990) Konishi et al.,"A Highly Attentuated Host Range-Restricted Vaccinia Virus Strain, NYVAC, Encoding the prince and the strain of the stra	13 Tu	,320	Kinney et al. (1997) "Construction of Infectious cDNA Clones for Dengue 2 Virus: Strain 16681 and Its	
Steamthous et al., "Vaccine development against infection with Helicobacter pylori," Br. Med. Bull. 54:229-41 (1998)			Kinney et al., "Recombinant Vaccinia Virus/Benezuelan Equine Encephalitis (VEE) Virus Protects Mice	
6, interleukin 12 and interferon □," Proc. Nat'l. Acad. Sci. USA 93:2879 (1996) Kilnman, D.M. et al., "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," Journal of Immunology, 158:3635-3639 (1997) Kilnman, D.M. et al., "Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) Kobyashi, Yuzuru et al., "Antigenic Analysis of Japanese Encephalitis Virus by Using Monoclonal Antibodies," Infect. Immun. 44:117 (1984) Kochel, Tadeusz et al., "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," Vaccine 15:547-552 (1997) Kodama et al., "Type I macrophage scavenger receptor contains -helical and collagen-like coiled coils," Nature 343:531-535 (1990) Konishi et al.,"A Highly Attentuated Host Range-Restricted Vaccinia Virus Strain, NYVAC, Encoding the prM. E and NS1 Genes of Japanese Encephalitis Virus Prevents JEV Viremia in Swine," Virology 190:454 (1992) Koopman et al., "Generation, intracellular transport and loading of peptides associated with MHC class 1 molecules," Curr. Opin. Immunol. 9:80-88 (1997) Kramer and Fritz, "Oligonucleotide-Directed Construction of Mutations via Gapped Duplex DNA," Methods in Enzymol. 154:350-367 (1987) Kramer et al. "Improved Enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations," Nucl. Acids Res. 16:7207 (1988) Kramer et al., "Different Base/Base Mismatches Are Corrected with Different Efficiencies by the Methyl-Directed DNA Mismatch-Repair System of E. coli," Cell 38:879-887 (1984) Kramer et al., "The gapped duplex DNA approach to oligonucleotide-directed mutation construction," Nucl. Acids Res. 12:9441-9456 (1984) Krieger, M. et al., "Molecular Flypaper, Atherosclerosis, and Host Defense: Structure and Function of the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992) Krieger,	The	322	Kleanthous et al., "Vaccine development against infection with Helicobacter pylori," Br. Med. Bull.	
Kilnman, D.M. et al., "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," Journal of Immunology, 18s.36s3-3639 (1997) Kobayash et al., "Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989) Kobyashi, Yuzuru et al., "Antigenic Analysis of Japanese Encephalitis Virus by Using Monoclonal Antibodies," Infect. Immun. 44:117 (1984) Kochel, Tadeusz et al., "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," Vaccine 15:547-552 (1997) Kodma et al., "Type I macrophage scavenger receptor contains -helical and collagen-like coiled coils," Nature 343:531-535 (1990) Konishi et al.,"A Highly Attentuated Host Range-Restricted Vaccinia Virus Strain, NYVAC, Encoding the prM, E and NS1 Genes of Japanese Encephalitis Virus Prevents JEV Viremia in Swine," Virology 190:454 (1992) Koopman et al., "Generation, intracellular transport and loading of peptides associated with MHC class 1 molecules," Curr. Opin. Immunol. 9:80-88 (1997) Kramer and Fritz, "Oligonucleotide-Directed Construction of Mutations via Gapped Duplex DNA," Methods in Enzymol. 154:350-367 (1987) Kramer et al. "Improved Enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations," Nucl. Acids Res. 16:7207 (1988) Kramer et al., "Different Base/Base Mismatches Are Corrected with Different Efficiencies by the Methyl-Directed DNA Mismatch-Repair System of E. coli," Cell 38:879-887 (1984) Kramer et al., "The gapped duplex DNA approach to oligonucleotide-directed mutation construction," Nucl. Acids Res. 12:9441-9456 (1994) Krieger, M. et al., "Molecular Flypaper, Atherosclerosis, and Host Defense: Structure and Function of the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992) Krieger al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amin	Not	اما	Klinman et al., "CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin	
Kobayashi et al., "Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic Effects an Human Lymphocytes," J. Exp. Med. 170:827 (1989)	ev	234	Klinman, D.M. et al., "Contribution of CpG Motifs to the Immunogenicity of DNA Vaccines," Journal of	
Kobyashi, Yuzuru et al., "Antigenic Analysis of Japanese Encephalitis Virus by Using Monoclonal Antibodies," Infect. Immun. 44:117 (1984) Kochel, Tadeusz et al., "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," Vaccine 15:547-552 (1997) 238	free		Kobayashi et al.,"Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A	
Cochel, Tadeusz et al., "Inoculation of plasmids expressing the dengue-2 envelope gene elicit neutralizing antibodies in mice," Vaccine 15:547-552 (1997) 238		236	Kobyashi, Yuzuru et al., "Antigenic Analysis of Japanese Encephalitis Virus by Using Monoclonal Antibodies," Infect. Immun. 44:117 (1984)	
238 Kodama et al., "Type I macrophage scavenger receptor contains -helical and collagen-like coiled coils," Nature 343:531-535 (1990)	thi	1V Vocabel Tadayan et al. Was substituted for a superscient the density of any state of the state of the substitute of the superscient the density of the substitute of the superscient the density of the substitute of the superscient the density of the substitute of the superscient th		
Constitution of Mutations via Gapped Duplex DNA," Construction of Mutations via Gapped Duplex DNA, Con			Kodama et al., "Type I macrophage scavenger receptor contains -helical and collagen-like coiled coils,"	
1 molecules," Curr. Opin. Immunol. 9:80-88 (1997) Kramer and Fritz, "Oligonucleotide-Directed Construction of Mutations via Gapped Duplex DNA," Methods in Enzymol. 154:350-367 (1987) Kramer et al. "Improved Enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations," Nucl. Acids Res. 16:7207 (1988) Kramer et al., "Different Base/Base Mismatches Are Corrected with Different Efficiencies by the Methyl-Directed DNA Mismatch-Repair System of E. coli," Cell 38:879-887 (1984) Kramer et al., "The gapped duplex DNA approach to oligonucleotide-directed mutation construction," Nucl. Acids Res. 12:9441-9456 (1984) Krieg et al., "CpG motifs in bacterial DNA trigger direct B-cell activation," Nature 374:546 (1995) Krieger, M. et al., "Molecular Flypaper, Atherosclerosis, and Host Defense: Structure and Function of the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992) Kruse et al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid	V	239	prM, E and NS1 Genes of Japanese Encephalitis Virus Prevents JEV Viremia in Swine," Virology	
Kramer and Fritz, "Oligonucleotide-Directed Construction of Mutations via Gapped Duplex DNA," Methods in Enzymol. 154:350-367 (1987) Kramer et al. "Improved Enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations," Nucl. Acids Res. 16:7207 (1988) Kramer et al., "Different Base/Base Mismatches Are Corrected with Different Efficiencies by the Methyl-Directed DNA Mismatch-Repair System of E. coli," Cell 38:879-887 (1984) Kramer et al., "The gapped duplex DNA approach to oligonucleotide-directed mutation construction," Nucl. Acids Res. 12:9441-9456 (1984) Krieg et al., "CpG motifs in bacterial DNA trigger direct B-cell activation," Nature 374:546 (1995) Krieger, M. et al., "Molecular Flypaper, Atherosclerosis, and Host Defense: Structure and Function of the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992) Kruse et al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid	POT	240		
Kramer et al. "Improved Enzymatic in vitro reactions in the gapped duplex DNA approach to oligonucleotide-directed construction of mutations," Nucl. Acids Res. 16:7207 (1988) Kramer et al., "Different Base/Base Mismatches Are Corrected with Different Efficiencies by the Methyl-Directed DNA Mismatch-Repair System of E. coli," Cell 38:879-887 (1984) Kramer et al., "The gapped duplex DNA approach to oligonucleotide-directed mutation construction," Nucl. Acids Res. 12:9441-9456 (1984) Krieg et al., "CpG motifs in bacterial DNA trigger direct B-cell activation," Nature 374:546 (1995) Krieger, M. et al., "Molecular Flypaper, Atherosclerosis, and Host Defense: Structure and Function of the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992) Kruse et al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid	in	241	Kramer and Fritz, "Oligonucleotide-Directed Construction of Mutations via Gapped Duplex DNA,"	
Kramer et al., "Different Base/Base Mismatches Are Corrected with Different Efficiencies by the Methyl- Directed DNA Mismatch-Repair System of E. coli," Cell 38:879-887 (1984) Kramer et al., "The gapped duplex DNA approach to oligonucleotide-directed mutation construction," Nucl. Acids Res. 12:9441-9456 (1984) Krieg et al., "CpG motifs in bacterial DNA trigger direct B-cell activation," Nature 374:546 (1995) Krieger, M. et al., "Molecular Flypaper, Atherosclerosis, and Host Defense: Structure and Function of the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992) Kruse et al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid	fu	242	Kramer et al. "Improved Enzymatic in vitro reactions in the gapped duplex DNA approach to	
Nucl. Acids Res. 12:9441-9456 (1984) 245 Krieg et al., "CpG motifs in bacterial DNA trigger direct B-cell activation," Nature 374:546 (1995) 246 Krieger, M. et al., "Molecular Flypaper, Atherosclerosis, and Host Defense: Structure and Function of the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992) 247 Kruse et al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid	1	243	Kramer et al., "Different Base/Base Mismatches Are Corrected with Different Efficiencies by the Methyl-	
246 Krieger, M. et al., "Molecular Flypaper, Atherosclerosis, and Host Defense: Structure and Function of the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992) Kruse et al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid		244	Nucl. Acids Res. 12:9441-9456 (1984)	
the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-609 (1992) Kruse et al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid		16.1 A -1 160.0 - A -1 10.10 - A -1 10.14 A -1 - A -1 10.14 A -1 - A		
Kruse et al., "Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid		246	the Macrophage Scavenger Receptor," Cold Spring Harbor Symposia on Quantitative Biology 57:605-	
1 10 placement, Eliber 6. 11:0201 0214 (1002)	1	247		

	, [
Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/P INFORMATION DISCLOSUS STATEMENT BY APPLICANT

(use as many sheets as necessary)

	omplete if Known	
Application Number	09/724,869	
Filing Date	November 28, 20	000 RECEIVED
First Named Inventor	Juha Punnonen	
Group Art Unit	1627	JUN 1 0 2002
Examiner Name	Unassigned	
Attorney Docket Number	02-030310US	TECH CENTER 1600/2900
Date Submitted	May 21, 2002	1EON OLIVIEN 1000/2500

1,57	248	Kuchroo et al., "B7-1 and B7-2 Costimulatory Molecules Activate Differentially the Th1/Th2		
NOT.	270	Developmental Pathways: Application to Autoimmune Disease Therapy," Cell 80:707 (1995)		
on	249	Kunkel et al.,"Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," Methods in		
		Enzymol. 154:367-382 (1985)		
	250	Kunkel, "The efficiency of oligonucleotide directed mutagenesis" Nucleic acids & Molecular Biology 2:		
10	230	124-135 (1988)		
THE	251	Kunkel, "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," Proc. Nat'l. Acad.		
	231	Sci. USA 82:488-492 (1985)		
Q_1 :	252	Lagranderie et al. (1993) "BCG-induced protection in guinea pigs vaccinated and challenged via the		
Pelvi	232	respiratory route." Tubercle and Lung Disease 74:38-46		
	253	Lai et al. (1991) "Infectious RNA transcribed from stabily cloned full-length cDNA of dengue type 4		
1 1	255	Virus." Proc. Nat'l Acad. Sci. USA 88:5139-5143		
	254	Lanar et al. (1996) "Attanuated Vaccinia Virus-Circumsporoziote Protein Recombinants Confer	\neg	
~	254	Protection against Rodent Malaria." Infect Immun 64:1666-1671		
	OFF	Lanciotti et al. (1994) "Molecular evolution and epidemology of dengue-3 viruses." J Gen Virol. 75:65-		
•	255	75		
	256	Laud et al., Human Immunol. 50:91-102 (1996)		
	200			
	257	Larsen et al., Long Term acceptance of Skin and Cardiac Allografts After Blocking CD40 and CD28		
		Pathways,"Nature 381: 434 (1996).		
	258	Leary et al.,"Active Immunization with Recombinent V Antigen from Yersinia Pestis Protects Mice		
		against Plague," Infect. Immun. 3:2854 (1995)		
	259	Lee et al., (1997) "Generation of an Infectious cDNA of a highly cardiovirulent coxsakievirus B3(CVB3m)		
		and comparasion to other infectious CVB cDNAs." Virus Res 50:255-235		
	260	Lee et al., "Optimal Induction of Hepatitis C Virus Envelope-Specific Immunity by Bicistronic Plasmid	1	
		DNA Inoculation with the Granulocyte-Macrophage Colony-Stimulating Facter Gene," J. Virol 72:8430-6		
		(1998)		
1 1	261	Lehrer et al. (1998) "Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis." FEMS	l	
		Immunol. Med. Mircobiol. 21:71-77		
	262	Leung et al. (1989) Technique 1(1):11-15		
$\vdash \vdash \vdash$		Liet of (1007) IC massion of the Human Davillement To a 4414 Consid Davids in C. 1. 1111		
1	263	Li et al. (1997) "Expression of the Human Papillomavirus Type 11 L1 Capsid Protein in Escherichia coli.		
\vdash		" J. Virol 71(4):2988-2995		
	264	Li et al.,"Cloning and functional characterization of a subunit of the transporter associated with antigen	1	
		processing," Proc. Natl. Acad. Sci USA 94: 8708-8713 (1997).		
Not	265	Liao et al. (1990) Gene 107-111	ħ	
200		Liao et al., STRL22 is a Receptor for the CC Chemokine MIP-3α," Biochem. and Biophys. Comms. 236:	{}	
		212-217 (1997).r	K	
		Liblau et al. "Th1 and Th2 CD4+ cells in the pathogenesis of organ-specific autoimmune diseases,"		
file	267	Immunol. Today 16:34-38 (1995)	- 1	
U 0		Liem et al. (1994) Nucleic Acids Res 22(9):1613-1619		
How	268	Lient et al. (1994) Nucleic Acius nes 22(9).1013-1019		
4		· · · · · · · · · · · · · · · · · · ·		

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ORIGINALLY FILED

JUN 0 5 2002 u

Application

Application

Name

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

	Complete if Known		
	Application Number	09/724,869	
C	⊋Bing Date	November 28, 2000 CVC	
Ī	First Named Inventor	Juha Punnonen	
	Group Art Unit	1627 JUN 1 0 2002	
	Examiner Name	Unassigned	
	Attorney Docket Number	02-030310US TECH CENTER 1600/2900	
	Date Submitted	May 21, 2002	

	,	
With	269	Lieschke et al.,"Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo," Nature Biotech. 15:35 (1997)
340	270	Limbach and Paoletti (1996) "Non-replicating expression vectors: applications in vaccine development
1700 210		and gene therapy." Epidemol. Infect. 116:241-256
ì	271	Lowe et al. (1997) "Human Papillamavirus Typw 2 (HPV-11) Nutralizing Antibobies in the Serum and
ا ا	2/1	Genitial Mucosal Secretions of African Green Monkeys Immunized with HPV-11 Virus-like particles
		Expressed in Yeast." J. Invect Dis 176:1141-1145
	272	Lowman, Henry B. and Jame A. Wells, "Affinity Maturation of Human Growth Hormone by Monovalent
U	212	Phage Display," J. Mol. biol. 234:564-578 (1993)
	273	Lowman, Henry B. and James A. Wells, "Monovalent Phage Display: A Method for Selecting Variant
11 -	2/3	Proteins from Random Libraries," Methods: A Companion to Methods Enz. 3(3):205-216 (1991)
NO.	274	Lu, Zhijian et al., "Expression of Thioredoxin Random Peptide Libraries on the Escherichia coli Cell
11 11	214	Surface as Functional Fusions to Flagellin: A System Designed for Exploring Protein-Protein
1.1-14	r.	Interactions," Bio/Technology 13:366-372 (1995)
V	275	Luytjes et al. (1989) "Amplification, Expressionand Packaging of a Foreign Gene by Influenza Virus."
1700	2/3	Cell 59:1107-1113
i	276	MacKay et al. (1981) "Production of immunology active surface of hepatitis B virus by Escherichia coli."
3	2/0	Proc. Natl. Acad. Sci USA 78:4510-4514
,	277	Mandl et al. (1997) "Infectious cDNA clones of tick-borne encephalitis virus European subtype protopic
	211	strain Neudoerfl and high virulence strain Hypr." J. Gen. Virol 78:1049-1057
	278	Marchetti, Marta et al., "Protection against Helicobacter pylori infection in mice by intragastric
1 1	2/0	vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin
J		(LT) as adjuvant," Vaccine 16:33-7 (1998)
· Note	279	Marusina et al.,"Allelic Variation in the Mouse Tap-1 and Tap-2 Transporter Genes," J. Immunol.
NOF 279		158:5251-5256 (1997)
u	280	Mattheakis, Larry C. et al., "An in vitro polysome display system for identifying ligands from very large
200		peptide libraries," Proc. Nat'l. Acad. Sci. USA 91(19):9022-6 (1994)
. 4	281	McAtee, C. Patrick et al., "Identification of Potential Diagnostic and Vaccine Candidates of Helicobacter
170	201	pylori by "Proteome" Technologies," Helicobacter 3:163-9 (1998)
	289	McAtee, C. Patrick et al., "Identification of Potential Diagnostic and Vaccine Candidates of Helicobacter
60	, 203	pylori by Two-Dimensional Gel Electrophoresis, Sequence Analysis, and Serum Profiling," Clin. Diagn.
704		Lab. Immunol. 5:537-42 (1998)
MAD	290	McCutcheon et al. "A senstive ELISPOT assay to detect low-frequency human T lymphocytes,", J.
MOP	230	Immunol. Methods 210:149-66 (1997)
١٨.	201	McGregor, Duncan, "Selection of Proteins and Peptides from Libraries Displayed on Filamentous
12 291		Bacteriophage," Mol Biotechnol. 6(2):155-62 (1996)
٠,١	292	Melen et al., "Enzymatic Characterization of Interferon-Induced Antiviral GTPases Murine Mx1 and
	232	Human MxA Proteins," J. Biol, Chem. 269: 2009-2015 (1994).
	293	Mendoza, R.B. et al. (1997) "Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154)
	230	on gene immunization" J. Immunol Dec. 15;159(12):5777-81 ABSTRACT ONLY
	294	Metz et al. (1996) "Bicistronic and Two-Gene Retroviral Vectors for Using MDR1 as a Selectable Market
and a Therapeutic Gene." Virology 217:230-241		

	· ·		
Examine	r	Date	
Signatu	e	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

HUN 0 5 2002 Substitute for form 1449A-B/PTO
INFORMATION DISCLOSURE Complete if Known Application Number 09/724,869 November 28, 2000 Piling Date STATEMENT BY APPLICANT First Named Inventor Juha Punnonen **Group Art Unit** 1627 **Examiner Name** Unassigned (use as many sheets as necessary) **Attorney Docket Number** 02-030310US **Date Submitted** May 21, 2002

the	295	Meulenberg et al. (1998) "An Infectious cDNA Clone Porcine Reproductive and Respiratory Syndrome Virus." Coronaviruses and Arteriviruses 440:199-206				
ſ	296	Meulenberg et al. (1998) "Infectious Transcrips from Cloned Genome-Length cDNA of Porcine Reproductive and Respiratory Syndrome Virus." J. Virol. 72:380-387				
1	297	Meyer et al. (1998) "Bovine herpesvirus type 1 glycoprotein H is essential for penetration and and propagation in cell culture." <i>J. Gen Virol.</i> 79:1983-1987				
	298	Minshull, J. and Willem P.C. Stemmer, "Protein evolution by molecular breeding," Current Opinion in Chemical Biology 3:284-290 (1999)				
\cdot	299	Mittelholzer et al. (1997) "Generation of cytopathogenic RNA of classical swine fevor in persistently infected porcine cell lines." Virus Res 51:125-137				
	300	Monaco , "Pathways for the processing and presentation of antigens to T cells," J. Leukocyte Biol. 57:543-57 (1995)				
	301	Morita et al. (1987) "Recombinant vaccinia virus LC16m0 or LC1m8 that expresses hepatitus B surface antigen while preserving the attention of the parental virus." Vaccine 5:65-70				
	302	Mosmann and Coffman, Adv. Immunol. 46:111 (1989)				
	-303	Moss (1994) "Replicating and Host-Restricted Non-Replicating Vaccina Virus Vectors for Vaccine Development." Dev. Biol. Stand 82:55-63				
	304	Mundt and Vakharia (1996) "Synthetic transcripts of double-stranded Birnavirus genome are infectious." Proc Nat'l Acad. Sci USA 93:11131-11136				
KU	305	N. Miller et al., (1995) "Targeted vectors for gene therapy," FASEB J., 9, pp. 190-199.				
2	306	Nakamaye and Eckstein, "Inhibition of restriction endonuclease Nci I cleavage by phosphorothioate groups and its application to oligonucleotide-directed mutagenesis," Nucl. Acids Res. 14:9679-9698 (1986)				
M.	307	Nambiar et al.,"Total Synthesis and Cloning of a Gene Coding for the Ribonuclease S Protein," Science 223:1299-1301 (1984)				
The	308 ز	Nazerlan et al. (1996) "Protection and synerhism by Recombinant Fowl Pox Vaccines Expressing Genes from Marek's Disease Virus." Avian Dis. 40:368-376				
<u> </u>	309	Nemoto, Naoto et al., "In vitro virus: Bonding of mRNA bearing puromycin at the 3'-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro," FEBS Lett. 414(2):405-8 (1997)				
	310	Ness, J. et al., (1999) "DNA shuffling of subgenominc sequences of subtilisin." Nature Biotechnology 17:893-896.				
	311	Manually A.B. and William and and A.M. all and A.M. all and B. C. A. C. (100 A.) 21 A.C.				
	312	Ni and Barrett, "Nucleotide and deduced amino acid sequence of the structural protein genes of Japanese encephalitis viruses from different geographical locations," J. Gen. Virol. 76:401 (1995)				
^	313	Notka et al. (1999) "Constructon and Characterization of Recombinant VLPs and Semliki-Forest Virus Live Vectors for Comparative Evaluation in the SHIV Monkey Model." Biol Chem 380:341-352				
	314	O'Neil, Karyn T. et al., "Phage display: protein engineering by directed evolution," Curr. Opin. Struct. Biol. 5(4):443-9 (1995)				
	315	Oda Kobe J. Med. Sci. 22:123 (1976)				
Ψ		T q				
Exami	iner	er Date				
Signat	ture	Considered				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 0 5 2002 W

Substitute for form 1449A-B/PTO	Co	omplete if Known
201	Application Number	09/724,869
INFORMATION DISCLOSURE	Filing Date	November 28, 200
STATEMENT BY APPLICANT	First Named Inventor	Juha Punnonen
	Group Art Unit	1627 JUN 1 0 2002
	Examiner Name	Unassigned
(use as many sheets as necessary)	Attorney Docket Number	02-030310US TECH OF NITED 4000/0000
	Date Submitted	May 21, 2002 TECH CENTER 1600/2900

		Charles and a control of the land of the l		
The.	316	Oggioni, M.R. and Pozzi, G., "A host-vector system for heterologous gene expression in Streptococcus gordonii," Gene 169:85-90 (1996).		
ا د	317	Orme (1997) "Progress in the development of new vaccines against tuberculosis." Int. J. Tuberc. Jung. Dis 1:95-100		
	318	Ortmann et al.,"A Critical Role for Tapasin in the Assembly and Function of Multimeric MHC Class 1- TAP Complexes," Science 277: 1306-1309 (1997).		
	319	Paoletti et al. (1995) "Highly Attenuated Poxvirus: HYVAC, ALVAC and TROVAC," Dev Biol Stand 84:159-163		
	320	Park and RajBhandary (1998) "Tatracycline-Regulated Suppression of Amber Codons in Mammalian Cells." Mol Cell Biol 18:4418-4425		
	321	Parren, Paul W.H.I. et al., "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design," Immunol. Lett. 57:105-112 (1997)		
4	322	Parronchi et al., "IL-4 and IFN (□ and □) Exert Opposite Regulatory Effects on the Development of Cytolytic Potential by Th1 or Th2 Human T Cell Clones," J. Immunol. 149:2977 (1992)		
NOT	,323	Pascopella et al. (1994) "Identification of a genome fragment of Mycobacterium tuberculosis." Infectious Agents & Disease 2:282-284		
120	324	Pascopella et al. (1994) "Use of In Vivo complementation in Mycobacterium tuberculosis to identify a genomic fragment associated with virulence." Infection & Immunity 62(4):1313-1319		
TRU	325	Pasquini S. et al. (1997) " Cytokines and costimulatory molecules as genetic adjuvants" immunol Cell Biol Aug: 75(4):397-401 ABSTRACT ONLY		
1/2T	326	Patten, P.A. et al., "Applications of DNA Shuffling to Pharmaceuticals and Vaccines," Current Opinion in Biotechnology, 8:724-733 (1997)		
ines	327	Paul and Seder, "Lymphocyte Responses and Cytokines," Cell 76:241 (1994)		
Jiel -	328	Paulusma et al. (1996) "Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene." Science 271:1126-1128		
ij	329	Pelletier, Joelle N., (2001) "A Rachitt for our toolbox" Nature Biotechnology vol. 19, p. 314-315		
4	330	Peng et al. (1998) "Papillomavirus Virus-like Particles Can Deliver Defined CTL Epitopes to the MHC Class 1 Pathway." Virology 240:147-157		
	331	Penzes et al. (1996) "Replication and Packaging of Coronavirus Infectious Bronchitis Defective RNSa Lacking a Long Open Reading Frame." J. Virol 70:86660-8668		
1	332	Phizicky, Eric M. et al., "Protein-Protein Interactions: Methods for Detection and Analysis," Microbiol Rev. 59(1):94-123 (1995)		
NX	333	Pisetsky, D.S., "Immune Activation by Bacterial DNA: A New Genetic Code," Immunity 5: 303-310 (1996).		
tool	334	Pletney, A.G. et al., Chimeric Tick-Borne Encephalitis and Dengue Type 4 Viruses: Effects of Mutations on Neurovirulence in Mice," J. Virol. 67(8):4956-4963 (1993)		
Tan)335	Polo et al. (1999) "Stable alphavirus packaging cell lines for Sidbis virus-and Semlike Forest virus-derived vectors." Proc Nat'l Acad. Sci USA> 96:4598-4603		
Not	336	Porcelli (1995) Adv. Immunol 59:1		
~ 7	չ337	Powis et al.,"Polymorphism in a second ABC transporter gene located within the class II region of the human major hisotcompatibility complex,"Proc. Nat'l. Acad. Sci. USA 89:1463-1467 (1996)		
V		4		
Exami	iner	Date		
Signat	ignature Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Complete if Known				
Application Number	09/724,869			
Filing Date November 28, 2000				
First Named Inventor	Juha Punnonen		_	
Group Art Unit	1627	RECEIVEL	٠	
Examiner Name	Unassigned			
Attorney Docket Number	02-030310US	JUN 1 0 2002		
Date Submitted	May 21, 2002			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

		L Premack et al. (1996) Nature Med. 2:1174	0/2
	338	Premack et al. (1996) Nature Med. 2:1174	,,,
The	339	Pryor et al. (1998) "Growth restriction of dengue virus type 2 by site-specific mutagenesis of virus- encoded glycoproteins." <i>J. Gen Virol.</i> 79:2631-2639	
1000	340	Punnonen et al (1998) "Evolution of genetic vaccines by DNA shuffling." Keystone Symposia on Molecular and Cellular Biology, Molecular Aspects of Viral Immunity, Abstract #227, Tamarron, CO, February 16-20, 1998	
How	341	Punnonen et al. (1997) "Evolution of DNA Vaccine vectors by gene shuffling." The First Gordon Conference on Genetic Vaccines/DNA Vaccines, Plymouth State College, Plymouth, NH, July 20-25, 1997	
How	342	Punnonen et al. J. Exp Med. 185:993-1004	
HUTTE	343	Punnonen et al., "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells," Proc. Nat'l. Acad. Sci. USA 90:3730 (1993)	
世	344	Puri et al. (1998) "Complete Nucleotide Sequences Analysis of a Western Pacific Dengue-1 Virus Strain." Virus Genes 17:85-88	
i ^s	345	Racke, Michael K. et al., "Cytokine-induced Immune Deviation as a Therapy for Inflammatory Autoimmune Disease," J. Exp. Med. 180:1961-66 (1994)	
<i>j</i>	346	Rahden-staron et al. (1991) Biochem & Biophy Res. & Commun. 177(2):597-602	
V	347	Raj and Jones (1997) "Growth of infectious bronchitis virus vaccines in oviducts derived from oestrogen-treated chicks and embryos." <i>Vaccine</i> 15:163-168	
poter	348	Reiser et al., "Cloning and expression of a cDNA for the T-cell-activating protein TAP," Proc. Nat'l. Acad. Sci. USA 85:2255-2259 (1988)	
TW	349	Roden et al. (1996) "In Vitro Generation and TypeSpecific Neutralization of a Human Papillomavirus Type 16 Viron Pseudotype." <i>J. Virol.</i> 70:5875-5883	
j	350	Roggenkamp et al., "Passive Immunity to Infection with Yersinia spp. Mediated by Anti-Recombinant V Antigen is Dependent on Polymorphism of V Antigen," Infect. Immun. 65:446 (1997)	
1	351	Roncarolo et al. "Human T- and B-cell functions in SCID-hu mice," Semin. Immunol. 8: 207 (1996)	
	352	Sagazio et al. (1998) "Antigenic characterization of canine parvovirus strains isolated in Italy." <i>J. Virol. Methods</i> 73:197-200	
7	353	Saggio et al. (1995) "CNFT Variants with increased biological potency and receptor selectivity define a functional site of receptor interaction." <i>EMBO Journal</i> 14(13):3045-3054	
级人	∠3 54	Sakmar and Khorana, "Total synthesis and expression of a gene for the a-subunit of bovine rod outer segment guanine nucleotide-binding protein (transducin), Nucl. Acids Res. 14:6361-6372 (1988)	
Th)355	Sanz et al. (1994) "Genetic heterogeneity of the attachment glycoprotein G among A respiratory syncytial virusus." Virus Res 33:203-217	
Till	356	Saurmann et al. (1990) "Molecular Cloning and Characterization of a German HIV-1 Isolate." AIDS Res. Hum Retroviruses 6:813-823	
NET	, 357	Sayers et al. "Strand specific cleavage of phosphorothioate-containing DNA by reaction with restriction endonucleases in the presence of ethidium bromide,", Nucl. Acids Res. 16:803-814 (1988)	
~ 7	,		

	[
Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUN 0 5 2002 4

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

u C	omplete if Known
Application Number	09/724,869
Films Date First Named Inventor	November 28, 2000 R - C - V -
First Named Inventor	Juha Punnonen
Group Art Unit	1627 JUN 1 0 2002
Examiner Name	Unassigned
Attorney Docket Number	02-030310US TECH CENTER 1600/2900
Date Submitted	May 21, 2002

•				
357	Sayers et al., "5'-3' Exonucleases in phosphorothioat Nucl. Acids Res. 16:791-802 (1988)			
358	Schatz, Peter J. et al., "[10] Screening of Peptide Libraries Linked to lac Repressor," Methods Enzymol. 267:171-91 (1996)			
359	Schmaljohn, A.L. et al., "Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis," Nature 297:70 (1982)			
360	Schwarz et al. (1957) "Modification of Infevtious Boving and Development of a Vaccine." Proc Soc Exp. Biol March 2015.			
Zu 361	Schwarz et al. (1958) "Propagation and Modification of Porcine Kidney Tissue Culture." <i>Proc Soc. Exp. Biol. I</i>	Med 97:680-683		
7 362	Scott, Jamie K. and George P. Smith, "Searching for Science 249:386-388 (1990)	or Peptide Ligands with an Epitope Library,"		
363	Seliger et al., "TAP off - tumors on," Immunol. Today	18: 292-299 (1997).		
364	Sharma and Graham (1982) "Influence of Material Ar Cell-Associated ans Cell-Free Marek's Disease Vacci	ne." <i>Avian Dis</i> . 26:860-870		
365	Sheu et al. (1995) "Deletion or alteration of hydrophol domains of Hepatitis B Surface antigen enhances its p	roduction in Escherichia coli." 160(2):179-184		
366	Shouval et al. (1994) "Improved immunogenicity in Mice of a mammalian cell-derived recombinant hepatitis B Vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines." Vaccine 12(15):1453-1459			
o入 367	Sizemore et al., "Attenuated Shigella as a DNA Delivery Vehicle for DNA-Mediated Immunization," Science 270:299-302 (1995)			
368	Smith, "In Vitro Mutagenesis," Ann. Rev. Genet. 19:423-462 (1985)			
369	Sokolic et al. (1996) "A Bicistronic Retrovirus Vector Containing a Picornavirus InternationalRibosome Entry Site Allows for Correct of X-Linked CGD Selection for MDR1 Expression." Blood 87:42-50			
370	Soong et al. (1998) "DNA shuffling as a tool to evolve desired retrovial phenotypes." Abstracts of papers presented at the 1998 meeting on Gene Therapy, p. 228 Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, September 23-27, 1998			
371	Soong et al. (1998) "Directed evolution of novel retroviral tropisms by DNA shuffling." Abstract #97, Programs & Abstracts, 1st Annual Meeting of the American Society of Gene Therapy, Seattle, Washington, May 28-31, 1998			
372 372	papers presented at the 1998 meeting on Retrovirused Harbor, New York, May 26-31, 1998	Soong et al. (1998) "Directed evolution of novel retroviral tropisms by DNA shuffling." Abstracts of papers presented at the 1998 meeting on Retroviruses, Cold Springs Harbor Laboratory, Cold Spring		
leu 373	Sosnovtsev et al. (1998) "Cleavage of the Feline Cal Encoded Proteinase." <i>J. Virol</i> 72:3051-3059			
374	Srinivasan et al. (1987) "Molecular characterization of Gene 52:71-82	·		
375	Stemmer (1991) *A 20-Minute ethidium bromide/high-salt extraction protocol for plasmid DNA.* BioTechniques 10(6): 726			
376	Stemmer (1994) Nature 370:389			
xaminer		Poto		
		Date		
ignature		Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for

Substitute for form 1449A-B/PTO	C	omplete if Known
	Application Number	09/724,869
INFORMATION DISCLOSURE	,€#ng Date	November 28, 2000 ECFIVED
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Juha Punnonen
	Group Art Unit	1627
	Examiner Name	Unassigned JUN 1 0 2002
(use as many sheets as necessary)	Attorney Docket Number	02-030310US
	Date Submitted	02-030310US May 21, 2002 TECH CENTER 1600/2900

The	377	Stemmer (1996) *DNA sequence evolution by sexual PCR.* Experientia (Basel) 52(ABSTR): A25
3-	378	Stemmer (1998) "Directed evolution of proteins, pathways, episomes and viruses by DNA shuffling," FASEB Journal 12(8): A1303
1	379	Stemmer and Soong, (1999) "Molecular breeding of viruses for targeting and other clinical properties," Tumor Targeting 4:1-4
7	380	Stemmer et al. (1991) "Expression of antibody Fv Fragments specific for a heavy metal chelate (indium-EDTA) in E. coli." Journal of Cellular Biotechnology Supplement 0 (15 PART G):217
2	381	Stemmer et al. (1992) "Enzymatic inverse PCR: a restriction site independent, single-fragment method for high-efficiency, site-directed mutagenesis." BioTechniques 13(2): 214, 216, 218-220
7	382	Stemmer et al. (1993) "Increased antibody expression from Escherichia coli through wobble-base library mutagenesis by enzymatic inverse PCR>" Gene 123(1): 1-7
2	383	Stemmer et al. (1993) "Selection of an active single chain Fv antibody from a protein linker library prepared by enzymatic inverse PCR>" Biotechniques 14(2): 256-265
1	384	Stemmer et al. (1997) "Molecular evolution of genetic vaccines by DNA shuffling." FASEB Journal 11(9): A1124 17TH Intarnational Congress of BiochemSan Francisco, CA USA (2/24-29,)
HOT	385	Stemmer et al.,(1995) "Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides," Gene 164:49-53
٥١٧	386	Stemmer, "DNA shuffling by random fragmentation and reassembly: In vitro recombination for molecular evolution," Proc. Natl. Acad. Sci. USA 91:10747-10751 (1994)
gile	387	Stemmer, W.P.C., "Rapid evolution of a protein in vitro by DNA shuffling," Nature 370:389-391 (1994)
UX	388	Stemmer, W.P.C., "Searching Sequence Space," Biotechnology 13:549-553 (1995)
	389	Stemmer, W.P.C., "Sexual PCR and Assembly PCR," The Encyclopedia of Molecular Biology, VCH Publishers, New York pp. 447-457 (1996)
390 Stemmer, W.P.C., "The Evolution of Molecular Computation," Science 270:1510 (1995)		Stemmer, W.P.C., "The Evolution of Molecular Computation," Science 270:1510 (1995)
	391	Stern et al., "Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells," Proc. Nat'l. Acad. Sci. USA 87:6808 (1990)
J	392	Stohwasser et al., "Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: reciprocally regulated tissue expression of interferon -γ-modulated proteasome subunits," Eur. J. Immunol. 27:1182-1187 (1997)
tou	,393	Subbarao et al. (1993) Rescue of an Influenza A Virus Wild-type PB2 Gene and a Mutant Derivative Bearing a Site-Specific Temperature-sensitive and Attenuating Mutation. J. Virol. 67:7223-7228
The	394	Sugimoto et al. (1994) "Characteristics of an attenuated vaccinia virus strain, LC16m0 and It's recombinant virus vaccines." Vaccine 12:675-681
tow	395	Sugimoto et al. (1995) Retroviral Coexpression of a Multidrug Resistance Gene (MDR1) and Human a-Galactosidase A for Gene Therapy of Febry Disease." <i>Human Gene Ther</i> 6:905-915
Not	396	Tahara et al., "IL-12 Gene Therapy Using Direct Injection of Tumors with Genetically Engineered Autologous Fibroblasts," Human Gene Therapy 6:1607 (1995)
The	397	Tan et al., "Characterizationof Recombinant Extracellular Domain of Human Interleukin-10 Receptor," J. Biol. Chem. 270:12906 (1995)
1		
<u> </u>		

_v		
Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Approved for use through 10/31/99. OMB 0651-0031 Substitute for form 1449A-B/PTO - RADI Complete if Known November 28, 2000 RECEIVED

Juha Punnonen Application Number **№** Date INFORMATION DISCLOSURE JUN 1 0 2002 TECH CENTER 1600 2900 STATEMENT BY APPLICANT First Named Inventor 1627 **Group Art Unit** Unassigned **Examiner Name** (use as many sheets as necessary) Attorney Docket Number 02-030310US

May 21, 2002

Tang et al. (1992) "Genetic immunization is a simple method for eliciting an immune response." Nature 398 Pu. 356:152 Tang et al., "Vaccination onto bare skin," Nature 388: 729-730 (1997). 399 Tano et al. (1990) Proc. Nat'l Acad Sci USA 87:686-690 400 Tartagila et al. (1992) "NYVAC: A Highly Attenuated Strain of Vaccinia Virus." Virology 188:217-232 401 Tascon, Richard E. et al., "Vaccination against tuberculosis by DNA injection," Nat. Med. 2:888-92 402 Taylor et al., "The rapid generation of oligonucleotide-directed mutations at high frequency using 403 phosphorothioate-modified DNA," Nucl. Acids Res. 13:8765-8787 (1985) Taylor et al., "The use of phosphorothioate-modified DNA in restriction enzyme reactions to prepare 分式 404 nicked DNA," Nucl. Acids Res. 13:8749-8764 (1985) Thierfelder et al. "Requirement for Stat4 in interleukin-1-2-mediated responses of natural killer and T 405 cells", Nature 382:171 (1996) Todd (1974) "Development of Intranasal Vaccination for the Immunization of Cattle Against infectious 406 Bovine Rhinotrachetis." Can. Vet J. 15:257-259 Trudel et al., "pGATA: A Positive Selection Vector Based on the Toxicity of the Transcription Factor 407 GATA-1 to Bacteria," Biotechniques 20:684-693 (1996). Tytgat, G.N.,"Review article: practical management issues for the Helicobacter pylori-infected patient at 408 risk of gastric cancer,"Aliment. Pharmacol. Ther. 12(1):123-8 (1998) Ugen et al. (1994) "DNA inoculation as a novel vaccination method against retroviruses with rheumatic 409 disease associations." Immunol. Res. 13:154-162. Ulmer et al. (1993) "Heterologous protection against influenza by injection of DNA encoding a viral 410 protein." Science 259:1745 Ulmer et al. (1996) "ELI's coming: expression library immunization and vaccine antigen discovery." 411 Trends im Microbiology 4(5):170-171 Valle amd Falgout (1998) "Mutagenesis of the NS3 Protease of Dengue Virus Type 2." J. Virol 72:624-412 632 van Dinten et al. (1997) "An Infectious arterivirus cDNA clone." Proc. Nat'l Acad. Sci USA94:991-996 413 VanCott et al., "Antibodies with Specificity to Native gp120 and Neutralization Activity against Primary 414 Human Immunodeficiency Virus Type 1 Isolates Elicited by Immunization with Oligomeric gp160," J. Virol. 71:4319-4330 (1997) Vassilev et al. (1997) "Authentic and Chimeric Full-length Genomic cDNA Clones of Bovine Viral 415 Diarrhea Virus That Yeild Infectious Transcrips." J. Virol 71:471-487 Velzing et al. (1999) "Induction of protective immunity against Dengue virus type 2." Vaccine 17:1312-416 Villinger et al., "Comparative Sequence Analysis of Cytokine Genes from Human and Nonhuman 417 Primates," J. Immunol. 155:3946-3954 (1995) Walther et al. (1996) "Cell type specific and inducible promoters for vectors in gene therapy as an 418 approach for cell targeting." J. Mol. Med. 74:379-392

Date Submitted

-		
Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

_ C	omplete if Known	
Application Number	09/724,869	
Filing Date	November 28, 2000 RFCFVE	U
First Named Inventor	Juha Punnonen	
Group Art Unit	1627 HIN 1 0 2002	
Examiner Name	Unassigned	
Attorney Docket Number	02-030310US TECH CENTER 1600/2	2900
Date Submitted	May 21, 2002	-000

Tro	419	Wang et al. (1993) "DNA inoculation induces cross clade anti-HIV-1 responses." <i>Annals New York Acad. Sci</i> 186-196				
i	420	Wang et al. (1993) "Gene inoculation generates immune responses against human deficiency virus type 1." Proc. Nat'l Acad. Sci. USA 90:4156-4160				
://	421	Walunas et al., "CTLA-4 Can Function as a Negative Regulator of T Cell Activation," Immunity 1:405 (1994)				
NOT	422	Wells et al., "Cassette mutagenesis: an efficient method for generation of multiple mutations at defined sites," Gene 34:315-323 (1985)				
fre	423	Wells et al., "Importance of hydrogen-bond formation in stabilizing the transition state of subtilisin," Phil. Trans. R. Soc. Lond. A317:415-423 (1986)				
offer FOO	424	Wermeille, Joel et al., "The eradication treatments of Helicobacter pylori," Pharm. World Sci. 20:1-17 (1998)				
1	425	Whelan et al. (1995) "Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones." Proc. Nat'l. Acad. Sci. USA 92:8388-8392				
	426	Whitacre et al.,"Treatment of Autoimmune Disease by Oral Tolerance to Autoantigens," Clin. Immunol. Immunopathol. 80: S31-9 (1996).				
	427	Wiertz et al., "SEC61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction," Nature 384: 432 (1996).				
	428	Wiertz et al., "The Human Cytomegalovirus US11 Gene Product Dislocates MHC Class 1 Heavy Chains from the Endoplasmic Reticulum to the Cytosol," Cell 84: 769-779 (1996).				
	429	Williams et al. (1993) "Genetic Infection Induces Protective In Vivo Immune Response." DNA & Cell Biology 12(8):675-683				
	430	Williams et al. (1994) "Immunotherapeutic strategies targeting rheumatiod synovial T-cell receptors by DNA inoculation." Immunol. Res 13:145-153				
	431	Winther et al. (1998) "Viral-Induced Rhinitis." Am J. Rhinol 12:17-20				
	432	Wisniak et al. (1974) "Hydrogen Solubility in Joboba Oil." JAOCA 51:482-485				
	433	Wloch et al., "The Influence of DNA Sequence on the Immunostimulatory Properties of Plasmid DNA Vectors," Hum. Gene Ther. 9:1439-1447 (1998)				
	434	Woody, Mary Alice et al., "Staphylococcal enterotoxin B mutants (N23K and F44S): biological effects and vaccine potential in a mouse model," Vaccine 15(2):133-139 (1997)				
\(\sigma\)	435	Wright et al. (1998) "Humane endpoints are an objective measure of morbidity in Venezelan encephalomyelitis virus infection of mice,' Arch Virol 143:1155-1162				
$ \cdot $	436	Xiang et al. (1994) "A Simple method to test the ability of individual viral proteins to induce immune responses." J. Virological Methods 47:103-116				
	437	Xiang, Z. et al., "Manipulation of the Immune Response to a Plasmid-Encoded Viral Antigen by Coinoculation with Plasmids Expressing Cytokines," Immunity 2:129-135 (1995)				
,	438	Yanagi et al. (1997) "Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee." Proc Nat'l Acad. Sci. USA 94:8738-8743				
1	439	Yanagi et al. (1999) "In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone." <i>Proc. Nat'l Acad. Sci USA</i> 96:2291-2295				
V.	440	Yao et al. (1998) "Generation of Mutant Infectious Bursal Disease Virus That Does Not Cause Bursal				
	T					
Exami	ner	Date				
Signat	1	Considered				
		the state of the s				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

ha Juli		
B	omplete if Known	
W .	Application Number	09/724,869
ATE.	Application Number	November 28, 2000
	First Named Inventor	Juha Punnonen HEUEIVEU
	Group Art Unit	1627
	Examiner Name	Unassigned JUN (0 2002
<i>(</i>)	Attorney Docket Number	02-030310US
	Date Submitted	May 21, 2002 TECH CENTER 1600/290

		Leaions." J. Virol. 72:2647-2654			
the	, 441	Yu et al. (1995) "Functional cDNA Clones of the Human Respiratory Syncytial (RS) Virus" J. Virol 69:2412-2419			
ja	,442	Zamvil, Scott S. and Lawrence Steinman, "The T Lymphocyte in Experimental Allergic Encephalomyelitis," Ann. Rev. Immunol. 8:579-621 (1990)			
VOT	443	Zanelli et al. (1993) "Epitope mapping of human thyroid peroxidase defined seven epitopes reconized by sera from patients with thyroid pathologies." <i>Cell. & Mol Biol.</i> 39(5):491-501			
Frie	444	Zhang, J. et al., "Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening," Proc. Natl. Acad. Sci. USA 94:4504-4509 (1997)			
120	445	Zhong et al. (1998) "Idenification and Characterization of an RNA-Dependent RNA Polymerase Activity within the Nonstructural Protein 5B Region of Bovine Viral Diarrhea Virus," <i>J. Virol.</i> 72:9365-9369			
Fire too	446	Zhong, Weimin et al., "Therapeutic passive vaccination against chronic Lyme disease in mice," Proc. Nat'l. Acad. Sci. USA 94:12533-12538 (1997)			
pat	447	Zoller and Smith, "Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA," Nucl. Acids res. 10:6487-6500 (1982)			
	448	Zoller and Smith, "Oligonucleotide-Directed Mutagenesis: A Simple Method using Two Oligonucleotide Primers and a Single-Stranded DNA Template," Methods in Enzymol. 154:329-350 (1987)			
file	449	Zoller and Smith, "Oligonucleotide-Directed Mutagenesit of DNA Fragments Cloned into M13 Vectors," Methods in Enzymol. 100:468-500 (1983)			
Ta	450	Zou et al. (1995) "Structure-function analysis of the p35 subunit of mouse interleukin 12." J. Bio. Chem. 270(11):5864-5871			
	451	Zuschek et al. (1961) "Immunogenicity of 2 Infectious Bovine Rhinotracheitis Vaccines." <i>J. Am. Vet. Med. Assoc.</i> 139"236-237			
V	452	Zygraich et al. (1974) "In Vivo and In Vitro Properties of a Temperature Sensitive Mutant of Infectious Bovine Rhinotracheitis Virus." <i>Res. Vet. Sci.</i> 16:328-335			

JUN 0 5 2002

		d	
Examiner		Date	. 1 1
Signature	T. Wenril	Considered	6/11/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.